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ABSTRACT 
The hormone leptin is an important regulator of body weight and energy balance, 
while nitric oxide (NO) produced in the blood vessels is beneficial for preventing 
disease-induced impaired vasodilation and hypertension. Elevations in the free radical 
superoxide can result in impaired vasodilation through scavenging of NO. Omega 3 is a 
polyunsaturated fatty acid that is beneficial at reducing body weight and in lowering 
many cardiovascular risk factors like atherosclerosis. The present study was designed to 
examine the change in plasma concentrations of leptin, nitric oxide, and the antioxidant 
superoxide dismutase in addition to examining the association between leptin and NO in 
healthy normal weight adult female subjects before and following omega 3 intakes. 
Participants were randomly assigned to either a fish oil group (600 mg per day) or a 
control group (1000 mg of coconut oil per day) for 8 weeks. Results showed no 
significant difference in the percent change of leptin over the 8 week supplementation 
period for either group (15.3±31.9 for fish oil group, 7.83±27 for control group; 
p=0.763). The percent change in NO was similarly not significantly altered in either 
group (-1.97±22 decline in fish oil group, 11.8±53.9 in control group; p=0.960). 
Likewise, the percent change in superoxide dismutase for each group was not significant 
following 8 weeks of supplementation (fish oil group: 11.94±20.94; control group: 
11.8±53.9; p=0.362). The Pearson correlation co-efficient comparing the percent change 
of both leptin and NO was r2= -0.251 demonstrating a mildly negative, albeit 
insignificant, relationship between these factors. Together, these findings suggest that 
daily supplementation with 600 mg omega 3 in healthy females is not beneficial for 
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improving these cardiovascular risk markers. Future studies in this area should include 
male subjects as well as overweight subjects with larger doses of fish oil that are 
equivalent to three or more servings per week. The importance of gender cannot be 
underestimated since estrogen has protective effects in the vasculature of females that 
may have masked any further protective effects of the fish oil. In addition, overweight 
individuals are often leptin-resistant and develop impaired vasodilation resulting from 
superoxide-mediated scavenging of nitric oxide. Therefore, the reported antioxidant and 
weight loss properties of omega 3 supplementation may greatly benefit overweight 
individuals.  
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CHAPTER 1 
INTRODUCTION 
    It is estimated that more than one third of adults and almost 17% of youth in the 
United States of America are obese. Approximately 41 million women and 37 million 
men ages 20 and over were obese in 2009–20101.  Among children and adolescents aged 
2–19, there are more than 5 million girls and approximately 7 million boys who are 
obese. Given the high prevalence of obesity, obesity-related medical treatment accounts 
for nearly 10% of annual medical spending costs, estimated between $147 and $210 
billion dollars each year2. 
Obesity is considered as risk factor for many clinical conditions like diabetes, 
hypertension and cardiovascular disease (CVD). It is also related to the leading causes of 
death in the United States as heart disease and stroke are responsible for the mortality of 
about 750,000 people every year3. These devastating numbers indicate helpful strategies 
are desperately needed to assist in the battle against obesity and CVD. 
Despite the availability of promising medical and surgical options in the   
management and prevention of obesity, the prevalence of obesity has not declined 
although cardiovascular mortality rates have declined in many high-income countries4-6. 
At the same time, cardiovascular deaths and disease have rapidly increased in low- and 
middle-income countries, as over 80% of all global deaths caused by CVD diseases is 
found in these countries. In addition, it is estimated that by 2030, over 23 million people 
will die from CVD every year globally7. 
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One approach to managing obesity is through dieting and changing lifestyle 
habits. This type of management is becoming more prevalent between patients and health 
providers8. Among these kinds of treatments available is the use of certain nutrients or 
foods to help to control or even prevent many health problems including obesity and 
CVD. Polyunsaturated fatty acids, especially omega 3, have been considered a good 
choice to meet this demand. In recent studies it was shown that increasing omega 3 can 
reduce body weight9.  In addition, omega 3 consumption positively affects many CVD 
disease risk factors, including improvements in triglycerides, total cholesterol, and low 
density lipoprotein (LDL) cholesterol10. Moreover, many studies have shown that omega 
3 supplementation is associated with a lower risk of developing coronary artery disease 
and hypertension as well as reduced adiposity and serum cholesterol11,13. 
For better management and prevention of obesity and its negative impact on 
health, a proper understanding of the biological factors influencing body fat regulation 
are critical. Factors may include genetic and environmental effects as well as the role of 
adipose tissue as an active endocrine organ that produces different substances and 
hormones, one of which is leptin12. Leptin is secreted from the adipose tissue to maintain 
homeostatic control of adipose tissue mass in the body and body weight through 
regulating the activity of food intake, energy expenditure and metabolism 12. 
A prior study showed that a diet enriched in cholesterol and alpha linolenic acid 
(from flaxseeds) increased protein and mRNA expression of leptin in the adipose tissue 
of healthy rabbits16.  
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It is also important to understand the role of nitric oxide (NO) in the process of 
endothelium-dependent vascular relaxation as well as the scavenging of reactive oxygen 
species that develop during states of vascular stress and inflammation that accompany 
chronic pathological conditions like atherosclerosis, obesity, and diabetes. Leptin 
hormone increases the production of NO by endothelial nitric oxide synthase enzyme in 
the endothelial cells of blood vessels271 while superoxide dismutase enzyme increases the 
bioavailability of NO through reducing reactive oxygen species that scavenge NO14, 236. 
Many studies have focused mainly on the behavior of leptin and NO in 
experimental animals including genetically-modified rodents with few studies conducted 
on humans. To our knowledge, few research studies have examined the relationship 
between omega 3, leptin and NO in healthy human subjects. Therefore, the primary aim 
of this study will focus on the effects of omega 3 supplementation on NO and leptin as 
well as antioxidant superoxide dismutase which can improve NO bioavailability in 
healthy participants. It is predicted that omega 3 supplementation in healthy subjects will 
increase the bioavailability of NO and decreased super oxide radicals through increasing 
super oxide dismutase activity14-15. It is additionally predicted that omega 3 
supplementation may increase leptin concentrations in healthy subjects. This study will 
lay the groundwork for future investigations regarding the efficacy of omega 3 
supplementation for prevention of obesity and endothelial dysfunction.  
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Purpose of Study 
The primary purpose of this study is to compare the plasma concentrations of 
leptin in healthy adult women before and after omega 3 supplementation (600mg per day 
for eight weeks). A secondary purpose of this study is to compare the plasma 
concentrations of nitric oxide following the same dietary protocol. The tertiary purpose is 
to compare the plasma concentration of the antioxidant superoxide dismutase following 
the same dietary protocol. The quaternary purpose is to study the association between the 
concentration of leptin hormone and nitric oxide. 
                                                       
Aims and Hypotheses 
 Primary Aim: 
To examine the change in leptin hormone in healthy adults before and after omega 3 
supplementation (600mg per day for eight weeks). 
 Primary Hypothesis: 
Plasma leptin concentrations will not be changed after 8 weeks of daily omega 3 
supplementation in healthy individuals compared to participants consuming coconut oil 
(placebo). 
 Secondary Aim: 
To examine the effect of omega 3 supplementation on plasma nitric oxide levels in 
healthy adults following daily omega 3 intake (600mg per day for eight weeks). 
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 Secondary Hypothesis: 
There will be no change in plasma nitric oxide concentrations before and after 8 weeks of 
daily omega 3 supplementation in healthy adults compared to placebo-treated individuals. 
 Tertiary Aim: 
To examine the effect of omega 3 supplementation on plasma superoxide dismutase 
enzyme levels in healthy adults following daily omega 3 intake (600mg per day for eight 
weeks). 
 Tertiary Hypothesis: 
There will be no change in plasma superoxide dismutase concentrations before and after 
8 weeks of daily omega 3 supplementation in healthy adults compared to placebo-treated 
individuals. 
 Quaternary Aim: 
To examine the association between serum leptin and NO levels in healthy subjects 
before and after 8 weeks of daily omega 3 supplementation compared to placebo treated 
individuals. 
 Quaternary Hypothesis: 
There will be a negative association between serum leptin and serum NO before and after 
8 weeks of daily omega 3 supplementation in healthy adults compared to placebo treated 
individuals. 
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Limitations and Delimitations 
The main limitation in this study results from its being a secondary analysis of 
samples obtained from subjects that participated in a previous study under an already 
established study protocol. Another limitation is that all subjects who participated in the 
study were healthy females with no males or unhealthy subjects included. 
Additional limitations are subject compliance to minimize the ingestion of omega 
3 fatty acids and only consume either the placebo or fish oil capsules. All subjects were 
asked to complete a food frequency questionnaire to reduce this limitation by excluding 
subjects who reported normal consumption of 3.5 ounces of fish twice per week. To 
minimize the effects of physiological hormonal fluctuations, all measurements were 
performed at the same point in the menstrual cycle for each participant. Further 
limitations include the small sample size and short treatment time used for the study, as 
well as external factors such as stress. The results of this study are generalizable to 
individuals similar to the participants in the original study who were women aged 18-38 
years without medical or health complaints at the time of study. The participants attended 
a large university in the southwestern U.S. 
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CHAPTER 2 
 REVIEW OF LITERATURE 
Leptin 
 Obesity results from deviations in the status of energy balance from equilibrium 
(energy intake equal to energy expenditure) towards positive energy balance, with the 
extra energy stored as body fat. The regulation of energy expenditure and control of body 
weight is performed through the interaction of various peripheral and central systems 
with hormones like leptin serving as chemical messengers for communication between 
these systems. Leptin is a protein produced by adipose tissue that helps regulate the level 
of stored body fat by affecting satiety and energy intake. Moreover, altered signaling may 
disrupt this regulation thereby affecting energy balance. 
 The first assumptions that a hormone like leptin existed were based on the 
observation that animals and humans can, to an extent, maintain their weight for 
prolonged periods. Moreover, balancing energy intake and energy expenditure to 
maintain weight involves homeostatic controls12. This homeostasis is the result of 
interactions of biological factors such that any disturbance in body weight is corrected. 
The role of the central nervous system in the regulation of body weight was supported by 
evidence showing that lesions in the hypothalamus can cause obesity or leanness 
depending on the affected area (the ventromedial hypothalamus for obesity, and the 
lateral hypothalamus for leanness)17.  
These observations led to the discovery that the hypothalamus is involved in a 
feedback loop wherein it receives peripheral messages from adipose tissue about an 
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organism’s nutritional state and energy status18. Kennedy et al. proposed that the 
hypothalamus receives information from peripheral factors regarding the level of fat 
stores19. The hypothalamus, in turn, responds to this information by stimulating the 
modification of food intake.  
Colman et al found that parabiosis (in which two mice were surgically united so 
the exchange of blood is possible between the two members) of normal mice with obese 
diabetic mice (db/db) caused the normal mice to become hypoglycemic and rapidly lose 
weight, eventually resulting in death from starvation and indicating that the diabetic mice 
produced what was thought to be a satiety factor that caused the normal mice to lose 
weight20. In contrast, parabiosis of obese mice (ob/ob) with normal mice did not change 
the feeding behavior of the normal partners. Instead, weight gain was suppressed in obese 
mice and after separation, the obese mice started to gain weight again suggesting that the 
obese mice were not producing a satiety factor and that they were responsive to that 
factor produced by normal mice. This blood factor produced by normal mice, and 
overproduced by db/db mice, can normalize ob/ob mice while no benefit from the 
introduction of that factor in db/db mice is observed. Moreover, the blood-born elements 
produced by increased adiposity induced satiety in the normal rats20. 
In another parabiosis experiment, Hervey et al discovered that introducing a 
hypothalamic lesion in one of the pair induced hyperphagia and obesity while the normal 
partner to become thin and ate less21. Moreover, when a lesion was introduced to the 
hypothalamus of thin mice, it caused hyperphagia indicating that a part of their 
hypothalamus is responsible for the overfeeding. These results provided evidence for a 
feedback control of food intake. 
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The hormone leptin (derived from leptos, a Greek word meaning “thin”) was 
finally identified in 1995, when the gene responsible for encoding leptin (ob gene) was 
cloned in 1994 with the help of positional cloning22. According to researchers, ob gene 
expression increases in adipose tissue from obese ob/ob rats as a result of overfeeding 
and lesions to the hypothalamus. Similarly, ob gene expression is increased in humans in 
proportion to the severity of obesity indicating a role for this gene in the development of 
obesity22. 
 
Figure 1. 3D structure of leptin hormone. Image from maptest.rutgers.edu 
 
Ob is an 18kb gene located at chromosome 7 and is composed of three exons and 
two introns23,24. This gene encodes the hormone leptin, a 166 amino acid protein whose 
biologically active site is the intra-chain disulfide bond. Leptin is a four helix bundle, 
which is similar to the structure of helical cytokines of the hematopoietin family24.  
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Figure 2.  Leptin Molecule. Image from www.guidechem.com 
 
This protein is 84% similar to that of the rat indicating that it is well-conserved25. 
Leptin is produced and released by differentiated adipocytes. Since there is no evidence 
that the hormone is stored in large amounts, this led to the assumption that leptin is 
secreted through constitutive or regulated mechanisms. Leptin is also produced by other 
tissues including the fundus of the stomach, placenta, and mammary epithelium but in 
smaller amounts25,26. Yesim et al demonstrated that the concentration of leptin in breast 
milk correlated positively with serum leptin levels in the mother and negatively with 
serum insulin and thyroxine levels26. It is higher during the first 180 days of lactation in 
order to regulate energy metabolism in the neonate. In the stomach, the cells that produce 
leptin are located in the lower half of the gastric glands where it is secreted into the blood 
and gastric juices to acutely control satiety in combination with cholecystokinin (CCK) 
from the vagal nerve27. If leptin reaches the intestine, it can participate in food digestion 
and absorption, while the leptin receptors are located in the fundic and antral epithelial 
cells and most of these receptors are of the longest form, Ob-Rb, which has the longest 
intracellular domain27. In spite of the wide distribution of leptin production sites, adipose 
tissue is considered the main site for leptin synthesis since the correlation between blood 
leptin concentrations and the level of its mRNA in the adipose tissue is strong and 
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positive28,29. In addition, mRNA concentrations are increased in ventromedial 
hypothalamic lesions or with mutations in the receptor. 
Leptin is secreted from the adipose tissue to maintain homeostatic control of 
adipose tissue mass in the body through regulating the activity of feeding centers in the 
hypothalamus to control food intake, energy expenditure and metabolism. When the fat 
mass in the body decreases, the plasma level of leptin will decrease leading to an increase 
in the appetite and decrease energy expenditure in the body and increasing fat mass. 
Similarly, leptin levels will increase when there is a decrease in fat mass and depress 
appetite and reduce body weight. In addition, adipocyte size determines leptin synthesis 
and secretion as large adipocytes contain more leptin than smaller ones30. 
Therefore, leptin mRNA expression in adipose tissue and circulating leptin are 
increased in obese people and leptin is positively correlated with BMI and percent body 
fat30,31. In contrast, thin individuals and those showing progressive weight loss have low 
levels of leptin in the blood and low leptin mRNA expression in adipose tissue as their fat 
stores are low31. Considine et al showed that serum leptin levels in obese people were 
31.3±24.1 ng/ml in comparison to 7.5±9.3 ng/ml in thin subjects32. 
Although mutations of the ob gene in humans are rare, such mutations may cause 
hyperphagia, morbid obesity (in both humans and mice, its associated with normal birth 
weight followed by rapid development of obesity)33, and impair the hypothalamic 
hypogonadism axis34 (primary amenorrhea in females; signs of delayed fertility in males 
such as no beard, scanty axillary and pubic hair, bilateral gynecomastia with small penis 
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and testes)33. Furthermore, insulin levels are elevated and insulin resistance is worsened 
with age in humans with leptin deficiency35. 
Leptin Receptors (Ob-R) 
The leptin receptor is a member of the class I cytokine receptor family which 
includes the receptor for interleukin 6 (IL-6), leukemia inhibitory factor (LIF), and 
granulocyte-colony stimulating factor (GCSF). Baumann et al demonstrated that among 
the isoforms of leptin receptor Ob-Rb, the full length isoform can activate signaling 
pathways similar to that of the IL 6 inflammatory receptor36. 
Using expression cloning, Tartaglia et al 37 identified and isolated the leptin 
receptor from the choroid plexus of a mouse. The leptin receptor gene is located on 
chromosome 17 and consists of 18 exons and 17 introns. The leptin receptor is 1162 
amino acids38 and present mainly in the hypothalamus and cerebellum but is also 
expressed in other tissues including the stomach, placenta, and vasculature39. Variations 
in mRNA splicing of the Ob-R produces 6 isoforms of the receptor (Ob-Ra, Ob-Rb, Ob-
Rc, Ob-Rd, Ob-Re, Ob-Rf) 40. These isoforms are similar in their extracellular ligand 
binding domain at the amino terminals, but they vary significantly in the intracellular 
structure and in signaling at the carboxy terminal41. 
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Figure 3. The various isoforms of the leptin receptor. The Ob-Rb isoform share extracellular binding 
domains, but vary in the intracellular mofit. Ob-Rb is longest and.Ob-Re lacks the transmembrane and 
intracellular motifs. Image from Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000;62(1):413-437. 
Ob-Ra is considered a leptin hormone transporter. Its structure is similar to Ob-
Rb, except it lacks the cytoplasmic portion and therefore does not have signaling 
properties42. Ob-Rc is another short form of the receptor. Both Ob-Ra and Ob-Rc are 
expressed in significant concentrations in the choroid plexus and micro vessels 
suggesting that they act as blood-brain barrier transporters43. This occurs through 
transcytosis wherein leptin is transferred from blood to the cerebral spinal fluid (CSF), 
although concentrations are very low in CSF compared to the blood. 
The Ob-Re receptor lacks the intracellular and trans membrane domains. Thus, it 
is considered a circulatory receptor. The half-life and clearance rate of leptin are 
determined by this soluble receptor. Therefore it is important in the regulation of leptin 
bioavailability and activity. Guoqing et  al44 found that Ob-Re not only acts as a reservoir 
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of leptin in the circulation, it also plays a general role in reducing fat accumulation and 
preventing weight gain by lowering food consumption and increasing basal metabolic 
rate (BMR). Moreover, they concluded that Ob-Re expression is inversely correlated to 
body weight and leptin concentrations in obese humans having high leptin concentrations 
in the blood while Ob-Re expression remains similar to that of non-obese people. This 
results in elevated free leptin especially in leptin resistant obese individuals42. 
Ob-Rb receptor is considered the longest isoform and contains the intracellular 
domain important for the activation of signaling pathway that includes the enzymes JAK 
(Janus kinase) and STAT3 (signal transducers and activators of transcription)45. This 
receptor is highly expressed in the hypothalamic region that controls body weight 
indicative that leptin acts centrally on the hypothalamus to regulate body weight and 
energy expenditure. Central infusion of leptin into the cerebroventricular region has 
similar actions as endogenous leptin present in the peripheral circulation. Mutations in 
Ob-Rb are rare and have similar effects as mutations of the Ob gene including 
hyperphagia, obesity, and hypogonadism. In addition, mutations of the receptor gene may 
lead to impaired secretion of thyrotropin releasing hormone and growth hormone from 
the pituitary gland46. The signaling pathway through Ob-Rb involves leptin binding to the 
extracellular domain, leading to activation of JAK2 tyrosine kinase thereby enhancing 
tyrosine phosphorylation of specific sites on the leptin receptor and JAK2 to activate 
intracellular signaling. 
The three major sites of phosphorylation are Tyr985, Tyr1077, and Tyr1138. 
Tyr1138 uses JAK2 to stimulate the phosphorylation of (STAT3) to promote 
transcriptional effects and signaling47. In contrast, Tyr985 activates Tyrosine-protein 
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phosphatase non-receptor type 11 (PTPN 11) instead and also binds to an inhibitor of Ob-
Rb/JAK2 signaling called suppressor of cytokine signaling-3(SOCS3), and Tyr1077 uses 
STAT547. 
Several neurons in the hypothalamus are targets of leptin action through the 
neurotransmitters that they release including NPY (neuropeptide Y), POMC (pro-
opiomelanocortin), galanin, and orexin. The STAT3 signaling pathway is present in these 
neurons 48 as well as other neurons that express leptin receptors. Defects in STAT3 
signaling may interrupt the effect of leptin on POMC, but not NPY, suggesting that the 
inhibitory effect of leptin is controlled through different mechanisms49. The negative 
feedback control of STAT signaling is performed by SOCS proteins50, which contain  
src-homology domain (SH2) and c-terminal SOCS box51. Any defect in these 
mechanisms can lead to failure in the inhibitory mechanism of leptin signaling. 
Another pathway involved in leptin signaling transduction is called PI3K-PDE3B-
cAMP pathway. This pathway is found not only in the CNS52, but is also found in other 
tissues such as the insulin-producing pancreatic beta cells, hepatocytes, and adipocytes. 
In these cells, leptin activates an insulin-like pathway involving activation of PDE3B 
(PI3K dependent) and resultant reduction in intracellular cAMP53. The importance of 
cAMP in feeding and body weight regulation is supported by the evidence that when 
cAMP is injected centrally it causes increased feeding and induces NPY gene expression 
in the hypothalamus54. This pathway also interacts with the JAK2-STAT3 pathway as the 
PDE3 inhibition results in diminished leptin effects on STAT355. 
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Figure 4.  Leptin intracellular signal transduction in the hypothalamus.Leptin binds to (Ob-Rb) and 
induces activation of Janus kinase (JAK), receptor dimerization, and JAK-mediated phosphorylation of the 
intracellular part of the receptor, followed by phosphorylation and activation of signal transducer and 
activators of transcription-3 (STAT3). Activated STAT3 dimerizes, translocates to the nucleus and tans-
activates target genes, including suppressor of cytokine signaling-3 (SOCS3), neuropeptide Y (NPY) and 
proopiomelanocortin (POMC). Image from Sahu A. Leptin signaling in the hypothalamus: Emphasis on 
energy homeostasis and leptin resistance. Front Neuroendocrinol. 2003;24(4):225-253. 
 
Leptin controls energy regulation and feeding through the hypothalamus, which is 
considered the primary center of feeding regulation57. The binding sites of leptin include 
the arcuate, ventromedial and dorsomedial hypothalamic nuclei and neuronal circuits in 
the brainstem58. Pelleymounter et al59 demonstrated that the injection of leptin into these 
sites inhibits food intake to a greater degree than administering leptin peripherally. 
Steven et al56 showed that administration of exogenous leptin (recombinant human leptin 
injected subcutaneously) induces weight loss in lean individuals and in obese individuals, 
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even those with high endogenous leptin (indicating leptin resistance). Moreover, the 
weight loss was dose dependent with most of the loss occurring in adipose tissue.  
James et al60 showed that the release of leptin from adipocytes relies on activation 
of calcium-dependent channels that are influenced by insulin and glucose levels. 
Circulating leptin is present in a free form or bound to plasma proteins (soluble 
receptor)61. The relative amount of leptin bound to plasma proteins tends to be higher in 
lean persons in comparison to obese individuals, which affects the bioavailability of 
leptin28,62. 
 After leptin crosses the blood-brain barrier, it influences the activity of various 
orexigenic and anorexigenic neurons located in different regions of the hypothalamus to 
produce different neurotransmitter or neuropeptides. Leptin suppresses orexigenic 
neuropeptides including neuropeptide Y (NPY), melanin concentrating hormone (MCH), 
agouti-related protein (AgRP), galanin, orexin, and galanin like peptide (GALP). In 
contrast, leptin stimulates the anorexigenic neuropeptides such as proopiomelanocortin 
(POMC; a precursor of α-MSH that works through the MC4 receptor), cocaine and 
amphetamine regulated transcript (CART), neurotensin, and corticotropin releasing 
hormone (CRH)57,63.  The leptin receptor Ob-Rb is co-expressed with NPY, AgRP, 
POMC, and CART in the arcuate hypothalamus, NPY and AgRP are expressed in the 
medial arcuate nucleus, while POMC and CART are expressed in the lateral arcuate 
nucleus64.  
In addition to the effect of these neuropeptides on energy regulation and feeding 
behavior, these orexigenic and anorexigenic neuropeptides react with each other 65,66 as 
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the α-MSH does not inhibit the effect of NPY but inhibits MCH, while a melanocortin 
agonist inhibits NPY67, and GLP-1(glucagon like peptide-1) inhibits both MCH and 
NPY68. 
NPY, which is produced by neurons in the arcuate nucleus, is considered a strong 
appetite stimulator and is involved in the regulation of several pituitary hormones. For 
example, it suppresses growth hormone through the stimulation of somatostatin and 
suppression of gonadotropins, in addition to regulating the pituitary adrenal axis69 and 
participating in cardiovascular physiology and mood modulation. But in spite of its 
strong potential effect on feeding, NPY deficiency or lack of NPY Y1 receptors (involved 
in contraction of vascular smooth muscle cells) or NPY Y5 receptors does not result in 
gross reduction of feeding behavior or prevent mild late weight gain not does it impair 
the response to leptin70-72. In contrast, increased NPY in the brain leads to increased ob 
gene expression in white adipose tissue through stimulation of hyperinsulinemia73. 
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Figure 5. Action of leptin on the hypothalamus and peripheral organs (pancreas, liver, and skeletal 
muscle, Leptin produced by fat tissue will act on the hypothalamus by decreasing NPY which causes a 
reduction in appetite and body weight and increases energy expenditure, it also improves β cell function in 
the pancreas and glucose metabolism. Image from Meier U, Gressner AM. Endocrine regulation of energy 
metabolism: Review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and 
resistin. Clin Chem. 2004;50(9):1511-1525. 
 
Masako et al showed that melano-concentrating hormone (MCH) deficiency 
results in hypophagia and weight loss74. The resultant decrease in leptin concentrations 
should cause hyperphagia, but rather hypophagia was observed. This indicates that MCH 
is important in the stimulation of hyperphagia associated with leptin deficiency. In the 
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same experiments, Masako concluded that the expression of POMC in the arcuate 
nucleus is reduced as a result of the reduced leptin concentrations, although the MCH 
deficiency in lateral hypothalamic neurons can cause reduced POMC expression in the 
arcuate nucleus. 
MCH is a short-term appetite stimulant that does not activate sustained increases 
in food intake and weight gain. The axons of MCH neurons project to the cortex and 
tractus solitaries, parabrachial nucleus in hindbrain and are upregulated by fasting. In 
contrast, NPY plays a role in the regulation of food intake and causes acute hyperphagia 
and chronic weight gain with axons that project to the paraventicular and dorsomedial 
hypothalamic nuclei. NPY is up regulated by fasting and negatively affected by leptin 
and insulin75 and both NPY and MCH gene mutations in rats leads to normal feeding 
behaviors21 indicating they are not essential for normal eating.  
Katsunori et al found that mutation of serotonin 5-HT2C receptors in the lateral, 
arcuate, dorsomedial hypothalamus, and the paraventricular nuclei leads to the 
development of hyperphagia, late onset obesity and disturbance of leptin signaling76. 
Responses to external leptin administration were normal indicating that the action of 
serotonin receptors does not require leptin. 
Other neurotransmitters and peptides involved in the mechanism of leptin 
signaling in the hypothalamus include glucagon like peptide-1(GLP-1), urocortin, 
bombesin, and serotonin12. As mentioned, the orexigenic hormones that stimulate 
appetite through the arcuate nucleus are suppressed by leptin. However, both orexin and 
leptin interact centrally leading to increased heart rate and arterial pressure (especially 
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during stress) suggesting that they may act as a chemical mediator of hypertension 
associated with obesity77. Leptin interact with other neurotransmitters/neuropeptides 
centrally to regulate feeding, reproduction, immune and inflammatory response, 
hematopoiesis, angiogenesis, bone formation and wound healing through a complex 
network through the hypothalamus and other parts of the brain78. An example is the 
NPY/AgRP and POMC/CART neurons that project to the paraventricular nucleus to 
mediate the effect of leptin on the neuro-endocrine axis and autonomic function79. 
Leptin and Bone Metabolism 
Dietary weight loss takes place in both obese and lean people and is associated 
with decreased bone mass and changes in markers of bone formation80. Leptin plays a 
role in the altered bone metabolism81. Centrally, leptin regulates the expression of 
RANKL (receptor activator of nuclear factor kappa-B ligand). Through increased 
expression of CART, RANKL affects bone resorption through activation of osteoclasts. 
Leptin also acts on osteoblasts through the central activation of the sympathetic nervous 
system82. In the periphery, the effects of leptin’s effects include osteoblast activation, cell 
proliferation, collagen synthesis, and mineralization, although other factors may be 
involved such as variation in diets, level of physical activity and insulin sensitivity82. 
Leptin and Thyroid Hormone 
The thyroid hormones (T3 and ,T4) are secreted in response to stimulation of TSH 
released from the anterior pituitary gland. The concentrations of thyroid hormones are 
regulated by feedback mechanisms between the thyroid and the pituitary, which is under 
the control of the hypothalamus (paraventricular nucleus). The hypothalamus secretes 
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thyroid releasing hormone (TRH), which in turn, stimulates the release of TSH from the 
anterior pituitary. In fasting, the level of T3 and T4 are decreased in response to low TSH 
as a result of suppression of TRH. Legardi et al found that leptin administration during 
fasting normalizes thyroid hormone concentrations as a result of leptin-mediated 
prevention of reduced TRH in the hypothalamus83. 
Leptin and Regulation of Immunity 
Leptin increases the production of certain cytokines from the T cells like IL-2 and 
interferon-y (INF-Y) while it decreases IL-4 and plays an important role in the regulation 
of T helper balance Th1/Th2 as it increases the production of cytokines from 
macrophages84 and enhances the alloproliferative response of human peripheral blood 
lymphocytes85. Treatment with leptin also reduces apoptosis in the thymus85. Moreover, 
leptin deficiency in mice diminishes hematopoiesis and delays dermal wound healing 
while administration of leptin accelerates wound healing86,87. 
In the case of starvation, leptin concentrations decline with the reduction in 
adiposity which is accompanied by a decline in immune function to conserve energy 
expenditure for more important systems like the CNS and metabolism, a situation 
reversed by leptin administration88. Patients with lypodystrophy (chronic disease of fat 
tissue) have significantly reduced plasma leptin concentrations. Hamilton et al 
demonstrated another role of adipose tissue in the regulation of leptin secretion, where it 
was shown that the increased size of adipocytes affects the rate of Ob mRNA 
transcription leading to more leptin in the blood30. Serum leptin concentrations vary 
directly with percentage of body fat and there is a significant positive correlation between 
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BMI and leptin concentration89,90. Although serum and adipose tissue leptin 
concentrations are both increased in obese patients, these patients are leptin-resistant89.  
 Regarding food intake, leptin concentration does not change acutely following 
meals. Rather it requires chronic overfeeding to increase concentrations. Similarly, it 
takes hours from the start of a fast to measure decreases in leptin concentrations. 
Therefore, leptin cannot be considered a mediator of immediate post-meal satiety91,92. 
This is a possible explanation for the mild increase in leptin during short-term fasting 
because the body still has adequate fat stores that can be used to meet energy 
requirements93.  
Leptin exhibits a diurnal rhythm wherein the concentration is higher during the 
night compared to the day. This probably occurs to suppress appetite during sleep and 
increase activity and energy expenditure during the day94. Schoeller et al95 showed that 
reversing day/night patterns of subjects resulted in a similar reversal in the peak 
concentrations of leptin. Moreover, shifting meal times was accompanied by shifted 
leptin concentrations where peak levels were associated with the synthesis of cholesterol. 
Another study showed that leptin concentrations at 2:00 pm are 30-100% higher than 
serum leptin concentrations in the morning and early afternoon94.  
 Insulin is considered an important long-term regulator of leptin appearance. 
Increased insulin concentrations after a meal are associated with increased leptin mRNA 
concentrations about 6 hours later that were found to be in response to insulin as opposed 
to the meal96. Regarding long-term regulation, Korbonits et al found that six months after 
surgical removal of an insulinoma, the level of insulin declined and led to decreased BMI 
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and leptin in one subject92. Considine et al concluded that the role of insulin in the 
regulation of leptin concentrations depends on previous nutritional status89. Data from 
Mueller et al shows that leptin secretion is not stimulated directly by insulin but instead 
by the effects of insulin on glucose delivery and metabolism in the adipocytes90. 
Therefore, the quantity of glucose metabolized by adipocytes will lead to larger leptin 
responses. 
 Glucocorticoids increase the expression of leptin mRNA in adipose tissue 
resulting in increased circulating leptin, while increased intracellular cAMP decreases the 
expression 97,98. Although glucorticosteroids also stimulate the secretion of NPY from the 
hypothalamus, its effect is suppressed by leptin99. The effect of different glucocorticoids 
on leptin is variable. While dexamethasone and hydrocortisone increase leptin levels 
about 3-4 fold, other steroids like aldosterone are ineffective100. 
 Thyroid hormone is negatively associated with serum leptin concentrations 
whereas thyroid stimulating hormone is positively correlated with leptin101. Hector et al 
showed that administration of thyroid hormone lowers serum leptin concentrations102.    
A possible explanation for this relationship is that as thyroid hormone increases, leptin 
declines to reduce the catabolic state, since both hormones increase metabolic rate101. 
 Grunfeld et al showed that cytokines and endotoxins during infections may induce 
the secretion of leptin and its mRNA from adipose tissues103. Inflammatory factors like 
TNFα and interleukin-1 (IL-1) increase serum and adipose leptin levels and therefore 
may induce anorexia during infections103. Bornstein et al concluded that leptin also acts 
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as a stress-related hormone that may play a role in survival as a part of the host defense 
mechanism104. Therefore, decreased leptin might affect the ability of fight infections.  
 Matsuoka et al examined the magnitude of changes in serum leptin and body fat 
mass in relation to growth hormone secretion and found that growth hormone does not 
directly effect leptin levels105. Rather, a reduction in body fat mass causes reduced leptin 
concentrations. In turn, leptin acts as a messenger to regulate growth hormone secretion. 
Leptin resistance  
             Hyperleptinemia is defined as a state of elevated circulating leptin concentrations 
in response to increased caloric intake. This elevated state results in resistance to the 
catabolic activity, decrease feeding behavior and prevention of increased body weight 
and obesity in response to leptin (i.e., leptin resistance). Obesity has been associated with 
leptin resistance as well as insulin resistance, especially in type 2 diabetes106, as food 
intake promotes increased adiposity leading to cellular leptin resistance. However, leptin 
resistance can be found in normal weight rats as well107. In fact, Wang et al107 
demonstrated that induction of overfeeding in normal weight rats caused insulin and 
leptin resistance after just 3 days. This form of resistance is usually detected in the 
hypothalamus. Dominique et al108 further showed that high fat diets result in defective 
leptin signaling to the hypothalamus as well as defects in activating the STAT3 pathway. 
Obesity may further contribute to central leptin resistance by causing endoplasmic 
reticulum stress thereby affecting the ObRb109. 
 Leptin resistance can be found in cases of genetic mutations that cause deficiency 
in the production of leptin or its receptors, and can also be caused by defects in leptin 
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signaling. In the case of mutations of the gene responsible for leptin receptor formation, it 
was found that patients with a defect in this gene have high levels of leptin receptors that 
are not attached to the surface of target cells due to a lack of the trans membrane and 
intracellular domains. These free receptors circulate in the blood where they attach to 
leptin produced in the body thereby preventing the normal effects of leptin61. Defects in 
leptin signaling can be attributed to several factors: 
1) Saturable transport of leptin across the blood brain barrier110 
 This is supported by evidence showing the ratio between leptin in cerebral spinal 
fluid and plasma is lower in obese patients111 and the central administration of leptin in 
obese rats decreases food intake while peripheral administration does not cause the same 
effect112. This usually occurs with the development of obesity. 
2) Defect in leptin signaling in the neural cells 
 During a state of hyperleptinemia, the raised leptin concentrations stimulate the 
phosphorylation of Tyr985 in the ObRb limiting the signaling in this receptor. Moreover, 
hyperleptinemia increases SOCS3, which blunts the receptor signaling113. In addition, 
decreased STAT3 phosphorylation contributes to defective leptin signaling114,115. 
3) Defect in the neural pathway participating in leptin function 
 Disruption of leptin signaling through the melanocortin pathway, which normally 
functions to reduce food intake, may be caused by various genetic mutations in the 
melanocortin peptide or its receptor, pharmacological agents, as well as diseases or 
lesions in the hypothalamus116,117. 
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4) Increased adiposity and hyperleptinemia as a result of defects in tissues not 
related to leptin signaling pathways 
 These defects may include mitochondrial uncoupling that promotes leakage of 
electrons, thereby causing oxidative stress and preventing the transformation of fat 
energy into heat118. Leptin resistance can also be a consequence of an ionic imbalance of 
zinc, calcium, and magnesium in food resulting in oxidative stress and eventually leptin 
resistance, a situation that can be restored by antioxidant administration119. Moreover, 
Montague et al showed that deletion of a guanine nucleotide in codon 133 of the gene for 
leptin resulted in morbid obesity associated with low leptin concentrations in humans120.  
           Besides the presence in the CNS, leptin receptors (OB-Rb) are also found in aortic, 
umbilical, adipose and dermal micro vascular endothelial cells121, and the activation of 
these receptors causes tyrosine phosphorylation of the STAT3 pathway within these cells. 
Activation of this pathway promotes angiogenesis especially in the adipose tissue where 
it increases lipid release and oxidation as a part of the peripheral actions of leptin in the 
maintenance of energy homeostasis122. 
           Regarding leptin and atherosclerosis, Taleb et al demonstrated that atherosclerotic 
lesions in leptin-deficient mice are smaller in size compared to those without leptin 
deficiency123. They also documented a significant correlation between serum leptin levels 
and cardiovascular disease, especially atherosclerosis, which is carried through the 
immune pathway, as leptin induces the proliferation of immune and inflammatory cells in 
many diseases like colitis, diabetes, and atherosclerosis.   
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             Leptin also increases sympathetic outflow when administered intravenously or 
intracerebroventricularly causing increased blood pressure and heart rate124. In contrast, 
leptin-deficient obese rats have low blood pressure readings in comparison to normal rats 
and develop increased blood pressure after peripheral leptin administration125. This is 
attributed to the effects of leptin on renal sympathetic nerve activity even in the presence 
of central resistance to leptin for weight loss126. 
           Leptin induces coronary artery vasodilation and improves coronary blood flow up 
to 40% in some instances. This mechanism of vasodilation is endothelium-independent 
and does not occur through the NO mechanism127. However, this vasodilator effect 
requires high doses of leptin that are above levels found in morbidly obese people128, 
while hyperleptinemia in obese people can negatively affect myocardial function and lead 
to heart failure129. 
 Hyperleptinemia that presents in obesity and metabolic syndrome can cause 
oxidative stress and endothelial dysfunction, which leads to atherosclerosis130. In fact, 
there is a strong correlation of serum leptin concentrations with acute phase reactants 
markers like C reactive protein131 and evidence shows any defect in leptin signaling can 
work as a protector against atherosclerosis132. 
Leptin and diabetes 
 Exogenous administration of leptin in patients with type 1 diabetes mellitus 
corrected insulin deficiency and improved glucose and lipid profile although insulin 
therapy was not discontinued133. As most patients with type 2 diabetes mellitus are obese, 
leptin concentrations in those patients are high and concentrations in women are higher 
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than men. This is attributed to women having a higher fat percentage134. Therefore, type 2 
diabetic patients show a refractory response to the metabolic effect of leptin 
administration. However, the anti-diabetic benefits of leptin can be seen in thin patients 
with normal leptin concentrations135. On the other hand, diabetes does not seem to 
influence acute and chronic leptin concentrations. Rather, what raises the leptin 
concentration is the state of hyperinsulinemia in experimental techniques and after long 
durations136, which could be a result of the atrophic effect of insulin on adipocytes. 
 As leptin receptors are found on β cells in the pancreas, leptin can inhibit insulin 
production through the activation of ATP-sensitive K+ channels. This suppression of 
insulin by hyperleptinemia is associated with increased insulin insensitivity and can 
explain metabolic syndrome associated with insulin resistance137. In addition, leptin 
administration to leptin-deficient mice improves skeletal muscle sensitivity to insulin138, 
which is considered the predominant target of insulin-mediated glucose disposal. Leptin 
also induces insulin-dependent suppression of hepatic glucose output through modulating 
hepatic gluconeogenesis enzymes139. These effects of leptin on glucose homeostasis and 
insulin resistance in obese people occurs centrally through the proopiomelanocortin 
(POMC) neurons in the arcuate nucleus of the hypothalamus140. In certain other clinical 
diseases like lipodystrophy, a disorder of adipose tissue homeostasis, leptin 
administration also corrects hyperglycemia and insulin resistance that accompany the 
disease141. 
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Nitric Oxide and Endothelial Dysfunction 
Inflammation  
 Inflammation is the response of the immune system in living tissues to local 
injury or microscopic invaders. It leads to local accumulation of blood cells and fluids in 
order to isolate the causative microorganism and repair the injured area. The cells and the 
extracellular material in the injured area will release signals (chemical and physical), 
which initiate inflammatory reactions142. The chemical signals act on the microcirculation 
to increase fluid and white blood cell (leukocytes, lymphocytes, and plasma cells) 
exudates.  
In acute inflammation, two sets of vascular events occur. First, changes in 
vascular flow and caliber occur to control the amount of exudates at the inflammation 
site. Chemical mediators released at the site of inflammation cause the blood vessels to 
dilate and the venules to contract143. These events promote increased blood flow to the 
site of injury. Secondly, vascular permeability becomes altered. Increased leakage of 
particles and fluids through the vascular membrane leads to more protein loss, while 
larger particles like lipoprotein are retained144. The endothelial lining of micro-vessels act 
as an active barrier responsible for maintaining circulatory homeostasis by regulating the 
exchange between blood and tissues. This passage of protein and fluid through 
endothelial cell-cell junctions is also important in vascular inflammation as fluids and 
inflammatory cells pass through the endothelial membrane to the infected or inflamed 
tissue. This process is mediated by increased immune cells and inflammatory mediators 
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like histamine, thrombin, vascular endothelial growth factor, neutrophil and neutrophil 
related cytokines like interleukins (ILs) and tumor necrosis factor (TNF)145. 
 In general, the behavior of any living tissue in acute inflammation is controlled by 
both functional and structural events or changes that take place in the microcirculation. 
These changes include: impaired vasomotor function, recruitment of leukocytes, 
diminished endothelial barrier function145, angiogenesis, and increased thrombosis, which 
is characterized by increased tissue plasminogen activator inhibitor and decreased C 
anticoagulant pathways to inhibit fibrinolysis146. This inflammatory response is not 
associated with acute injuries, but also accompanies many pathological conditions like 
obesity, cancer, diabetes mellitus, and hypertension. Among these pathological 
conditions, atherosclerosis represents an example of chronic inflammation of blood 
vessels which can cause endothelial dysfunction147,148. 
Endothelial Dysfunction 
 The impairment of physiologic endothelium dependent relaxation may occur in 
hypertension, diabetes, hypercholesterolemia, and atherosclerosis149. Endothelial 
dysfunction broadly occurs when the physiologic and protective properties of the 
vascular endothelium are lost or damaged such as the damage that occurs during 
percutaneous procedures in coronary arteries. Alternatively, endothelial dysfunction can 
be a result of oxidative stress, hyperglycemia, advanced glycation end products, 
metabolic responses to free fatty acids, and inflammatory cytokines150-152. Endothelial 
dysfunction can be judged by assessing the vasodilator response. Two main vascular 
alterations that accompany micro vascular dysfunction: these alterations are the 
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generation of reactive oxygen species (ROS)153 and decreased availability of the 
endogenous vasodilator nitric oxide (NO)154. 
Nitric oxide (NO) 
Nitric oxide is a free radical gas molecule produced from the conversion of L-
arginine to L-citrulline by endothelial nitric oxide synthase (eNOS) in the endothelial 
cells of blood vessels (as described below)155. It is an uncharged molecule that is highly 
soluble in hydrophobic media, which is what enables it to diffuse easily through cell 
membranes. NO takes part in the vascular homeostasis and in the regulation of 
vasodilation and vasoconstriction through the increase of cGMP. It was discovered in 
1980 by Furchgott and Zawadiskii as an endothelial-derived relaxing factor154. In normal 
conditions, the endothelial cells produce NO in small amounts to maintain vascular tone. 
But the rate of synthesis is increased in response to chemical stimuli, such as thrombin, 
ADP, serotonin, acetylcholine, and bradykinin, or physical stimuli like shear stress and 
cyclic strain156.  
 NO is produced by nitric oxide synthase enzymes, which are hemoprotein 
enzymes that catalyze a five step electron oxidation of the terminal guanidine nitrogen 
atom of L-arginine to L-citrulline and NO157. NOS is composed of a N-terminal 
oxygenase domain and a C-terminal reductase domain with a calmodulin recognition 
sequence between them158. Activity of the enzyme requires the presence of flavin 
mononucleotide and flavin adenine dinucleotide, tetrahydrobiopterin (BH4), calcium, and 
heme159. As the calcium concentration inside endothelial cells increases, it affects the 
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ability of calmodulin to react with the transfer of electrons from NADPH to the heme 
iron thereby acting as a catalyst in the synthesis of NO160. 
 
Figure 6.The synthesis of NO by nitric oxide synthase. Image from       
http://en.wikipedia.org/wiki/Nitric_oxide_synthase 
 
NOS are also regulated by NO which can act as a negative feedback inhibitor of 
the enzyme activity as the NO molecule reacts with the ferrous hemoprotein part of the 
enzyme to temporarily inactivate NOS161.  Other factors that influence the activity of 
these enzymes include BH4 deficiency or L-arginine deficiency. In fact, the 
administration of L-arginine improves the enzyme function in rabbit thoracic aorta and, 
as a result, the availability of NO162. 
 In contrast, methylation of arginine by methyltransferase in healthy individuals 
results in asymmetric dimethyl arginine, which acts as an inhibitor of the enzyme163 as 
well as a vasoconstrictor that induces hypertension. Marked elevations in asymmetric 
dimethyl arginine levels are seen in certain diseases like hypertension, 
hypercholesterolemia, stroke, and diabetes mellitus164,165,166.   
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Figure 7.  Nitric oxide synthase isoforms. Image from 
https://www.caymanchem.com/pdfs/780001.pdf  
 
There are 3 isoforms of the nitric oxide synthase enzyme: neuronal (nNOS), 
endothelial (eNOS), and inducible (iNOS)167.The nNOS isoform is found mainly in the 
nervous system and produces NO in scanty amounts during normal physiological 
conditions. It plays a role in the process of memory168, feeding behaviors169, and 
communication in both peripheral and central neurons170. Inducible NOS produces NO as 
a response to microbial endotoxins as well as cytokines and the quantity of NO produced 
by iNOS are usually large167. NO produced by iNOS acts as a vasodilator to resist 
vasoconstriction that accompanies certain pathological conditions like septic shock167. 
              Increased production of superoxide (O2-) during inflammatory stress and high fat 
intake stimulates iNOS protein synthesis and this, in turn, causes more O2- production. 
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Superoxide is a scavenger of NO in the blood vessel wall resulting in the formation of 
peroxynitrite (ONOO-) causing impaired vasodilation171. Deficiency of eNOS in 
experiments conducted on mice is associated with clinical complications like 
atherosclerosis and hypertension172, vascular smooth muscle cell proliferation during 
injury173, hypercoagulability174, and increased diet-induced atherosclerosis175.  eNOS and 
nNOS are found in BAT (brown adipose tissue) and because NO inhibits cytochrome 
oxidase, NO participates in energy regulation of BAT through decreased mitochondrial 
respiration176.Ablation of iNOS in leptin-deficient mice leads to increased thermogenesis, 
body temperature and energy expenditure176 whereas abnormalities in eNOS may be 
associated with obesity and metabolic changes in diabetes. 
eNOS usually is activated by phosphorylation of the serine and threonine residues 
in the amino acid sequence of the enzyme177 by mechanical mediators like shear stress, or 
chemical mediators like acetylcholine, insulin and estrogen178 .leading to increase NO 
production. Importantly, eNOS production of NO is decreased in diabetes, hypertension, 
metabolic syndrome, obesity, and in response to inflammatory factors like IL-6 and TNF 
α179,180. Elevated NO concentrations negatively feedback to inhibit NOS and oxidized 
LDL limits NO activity181, while administration of L-arginine improves endothelial 
function in animals fed a high cholesterol diet. Oral administration of L-arginine in 
patients with heart failure showed improvement in forearm blood flow and increased 
distances during a 6-minute walk182. The administration of statins, which are 3-hydroxyl-
3-methylglutaryl coenzyme A reductase inhibitors, is used as first-line mechanism to 
prevent cardiovascular disease associated with atherosclerosis by reducing serum 
cholesterol. The administration of statins is associated with improvement of endothelial 
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function by removing oxidative stress and increasing NO bioavailability through 
increased eNOS activity, inhibition of eNOS uncoupling and reduced production of ROS 
from NADPH oxidase183,184. Sweazea et al185 showed that high fat and high sucrose diets 
in rats may cause oxidative stress and impaired vasodilation, although the mechanism is 
different between the two diets wherein high fat diet rats develop vascular dysfunction 
through scavenging of NO by O2-,while high sucrose diet rats develop dysfunction 
through overproduction of H2O2 Impaired vasodilation is also attributed to decreased 
vascular smooth muscle tone through decreases in calcium stores or reduced smooth 
muscle sensitivity to calcium186. 
 During hyperbaric oxygenation, eNOS regulates cerebral blood flow to protect the 
brain against ROS-induced vasoconstriction187. While apoE/eNOS knock-out mice show 
evidence of ischemic heart disease, left ventricular dysfunction, and aortic aneurysm, 
similar to what happens in atherosclerotic and cardiovascular diseases175. In addition, 
eNOS knockout mice are hypertensive despite the presence of other counter regulatory 
mechanisms like cardiac, neuronal, and hormonal188.  
Function of nitric oxide 
 NO has an important role in regulating vascular tone and blood flow as NO 
produced in the endothelium diffuses to smooth muscle cells causing them to relax, 
leading to vasodilation and lowering blood pressure190. 
Vascular endothelium and blood vessels contraction 
 The endothelial cells lining the lumen of blood vessels participate in the adjacent 
smooth muscle contractions189 and lead to the relaxation of arteries and veins through 
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stimulation of muscarinic receptors via the release of endothelial-derived relaxing factors 
(EDRFs). Acetylcholine binding to the muscarinic receptors may also activate the release 
of EDRFs190. This type of relaxation is more prevalent in arteries than veins, but it can be 
found in some large veins such as the pulmonary vein191. Absence of the endothelial 
lining prevents the vasodilator response to acetylcholine and instead causes contraction 
when large amounts of acetylcholine are administered192. Vasorelaxation induced by 
ATP, ADP, and increases in extracellular calcium are endothelium-dependent193. The 
endothelium can also be a source of vasoconstrictor signals where it can augment the 
contractions started by norepinephrine and prevent vasodilation by inhibition of 
cyclooxygenase and thromboxane synthase194,195. 
 Vasomotor reactivity of blood vessels is regulated by the close proximity 
of vascular smooth muscle cells and the adjacent endothelial cells192,196. Histological and 
physiological analyses show that the endothelial cell lining of blood vessels are separated 
from the smooth muscle cells by the internal elastic lamina197. Myoendothelial gap 
junctions (MEGJs) physically connect endothelial cells and smooth muscle cells198. 
Activation of endothelial cells by shear stress or activation of GPCR ligands (G protein 
coupled receptors) by acetylcholine198, increases calcium influx through receptor-
operated channels (ROC3) and store-operated channels (SOC3)199. As the concentration 
of intracellular calcium increases, two pathways become activated: EDHFs (endothelial-
derived hyperpolarizing factors) and EDRFs (endothelial-derived relaxing factor)190,200. 
EDRFs include NO, which diffuses through myoendothelial gap junctions to the smooth 
muscle cells to activate cGMP, as well as cyclooxygenase that produces prostaglandins, 
which react with a receptor on the smooth muscle surface called IRP to activate the 
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release of cAMP201. Activated cAMP and cGMP, in turn, activate calcium-dependent 
potassium channels leading to the inhibition of voltage-gated calcium channels resulting 
in decreased calcium concentrations in smooth muscle cells causing relaxation201. 
Increased concentrations of intracellular calcium in endothelial cells also stimulate 
EDHFs, which activate calcium- dependent potassium channels to increase intracellular 
potassium causing hyperpolarization of the endothelial cell membrane. The 
hyperpolarization is then transmitted to the smooth muscle cells by MEGJs and also 
causes the potassium to enter the elastic lamina space. Both actions cause smooth muscle 
hyperpolarization and inhibition of calcium channels resulting in smooth muscle cell 
relaxation202. Increased endothelial intracellular calcium concentrations also cause the 
production of superoxides from NADPH oxidase, cyclooxygenase, and eNOS. The 
superoxide can be converted to H2O2 by superoxide dismutase (SOD), which diffuses to 
smooth muscle cells to activate potassium channels and inhibit calcium202. In general 
vasodilation by EDHF occurs in the distal arterial segments rather than the proximal201. 
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Figure 8. Endothelial-dependent relaxing factors (EDRFs) and endothelial-dependent hyperpolarizing 
factors (EDHFs). Image from Kvietys PR, Granger DN. Role of reactive oxygen and nitrogen species in the 
vascular responses to inflammation. Free Radic Biol Med. 2012;52(3):556-592. 
 
Two main features of inflammation appear in the vascular endothelium: increased 
generation of ROS and decreased availability of NO200,153. The endothelial cells in 
cerebral blood vessels modify the vascular tone in response to the change in the partial 
pressure of carbon dioxide through a mechanism called chemo regulation203, During 
hypercapnia (increase the partial pressure of carbon dioxide), the endothelial cells 
produce vasodilators that  increase cerebral blood flow, and during hypocapnia the 
endothelial cells produces vasoconstrictors in form of NOS+ inhibitors and decrease 
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blood flow204, this mechanism is affected by certain vascular disease like subarachnoid  
hemorrhage, ischemic stroke, and brain trauma205. 
As discussed earlier, endothelial dysfunction can be caused by reduced NO 
availability, which can result from decreased eNOS gene expression or L-arginine 
deficiency206, NOS inhibition by asymmetric dimethyl arginine207, or caused by 
uncoupling of eNOS or tetrahydrobiopterin deficiency208. 
During the childbirth, certain physiological changes take place in the pulmonary 
blood vessels with the start of ventilation, which is represented in decreasing vascular 
resistance and increasing blood flow in the pulmonary blood vessels of the neonate with 
the initiation of ventilation and oxygenation. These physiological changes are attributed 
to an increase in eNOS gene expression and enzymatic activity and also increase NO 
production as a result of the enzyme activity209. In certain pathological conditions like 
persistent pulmonary hypertension of the neonates, which result from the failure of the 
normal physiological process to develop, there is a marked decrease in the mRNA of e 
NOS in the lung tissue210. 
Nitric oxide not only acts as a vasodilator, but also has anticoagulant and 
inflammatory effects, where it inhibits the adhesion of leukocytes to the endothelium of 
blood vessels in the early stage of inflammation211. Moreover,  any disturbance in the 
function of NO  in blood vessels may cause hypertension and ischemic stroke which can 
be due to the impaired vascular effects of NO as well as the disturbance in its 
antithrombotic effect212,213. NO is also involved in other mechanisms involving the 
regulation of platelet function and the reaction with hemoglobin and reactive oxygen 
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species214.NO modulates platelet-endothelium interactions and maintains blood flow 214. 
To maintain blood flow, there are three biochemical systems that suppress platelet 
activity:  prostacyclin, the ecto-AT(D)Pase, and NO. Prostacyclin results from 
endothelial metabolism of arachidonic acid and inhibits platelet aggregation through the 
cAMP mechanism while the ect-AT(D)Pase acts through ATP-induced platelet 
aggregation and through inhibiting thromboxane A2 receptors215,216. Since NO exerts its 
effect through cGMP production and ATPase dependent refilling of calcium stores,  this 
results in lower calcium that is available to interact with platelet aggregation 
mechanisms217 causing a decrease in platelet calcium during activation and  modification 
of the shape and cytoskeletal arrangement of platelets, leading to  platelet aggregations218. 
NO also decreases platelet plug formation through inhibition of active fibrinogen 
conformation of glycoprotein resulting in reduced cell receptors required for platelets to 
interact with each other and form a plug219. 
NO additionally induces apoptosis of megakaryocytes, which are responsible for 
platelets formation. Therefore NO controls both the production and function of 
platelets220. Macrophages induced by bacterial endotoxin show elevated levels of NOS 
and NO, which can have antibacterial effects221. 
NO produced by eNOS is also a neurotransmitter in the nerves that supply certain 
blood vessels like cerebral and penile vessels222.  
NO can form a complex with the hemoglobin molecule, which is important in 
hypoxic vasodilation. This process appears during situations of increased oxygen 
requirement like in certain regions of the brain or to the muscles during exercise. The Hb 
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molecule becomes S-nitrosylated when it reacts with NO to form SNO-Hb during the 
process of oxygenation in the lungs223,224. This molecule has vasodilator effects and leads 
to increased blood and oxygen supply to certain tissues during the non-pathological 
increase of metabolic activity225. Disorders of this mechanism are associated with 
congestive heart failure, pulmonary hypertension, and diabetes226,227,228. NO may also 
react with reactive oxygen species resulting in reduced bioavailability, which is 
considered one of the two main features of micro vascular dysfunction. 
Reactive oxygen species 
ROS are the product of aerobic respiration and substrate oxidation during 
physiological metabolism at the cellular level. Common enzymatic sources of ROS 
include the mitochondrial electron transport chain, xanthine oxidase, cytochrome p450 
monoxygenases, lipoxygenase, NADPH oxidase, and even nitric oxide synthase229. The 
ROS produced include superoxide (O2-), hydroxyl radical (OH-), hydrogen peroxide 
(H2O2), and peroxynitrite (ONOO-). The formation of ONOO- from the reaction of NO 
with O2-  is considered the primary source for the production of RNS (reactive nitrogen 
species), which are considered reactive neurotoxins230. These ROS can be used in low 
concentrations by the body in some normal physiological processes such as against 
microorganisms as part of the immune system and in intracellular signaling231,232. They 
may also participate in signaling inflammatory chemotaxis immune cells to the site of 
inflammation233, while high concentrations of these ROS or even incomplete removal of 
them may lead to what is called oxidative stress. Oxidative stress is involved in many 
pathological conditions like hypertension, diabetes, pulmonary hypertension234, and 
atherosclerosis235. Raised levels of ROS affect many biological mechanisms and 
43 
 
pathways like reducing the bioavailability of NO as superoxide ions scavenge NO 
forming ONOO-, leading to endothelial dysfunction. This also affects mitochondrial 
function, cellular growth through DNA damage through superoxide toxicity or by lipid 
peroxidation, or through affecting many cellular processes like cell signaling and 
apoptosis156. 
 
Figure  9. Generation and metabolism of reactive oxygen species (ROS). Superoxide is produced by 
NADPH oxidase, xanthine oxidase, nitric oxide synthase (NOS), lipoxygenase, and mitochondrial enzymes, 
Superoxide is converted by superoxide dismutase (SOD) to H2O2, which is reduced to water by catalase, 
glutathione peroxidases (GPx), and peroxiredoxins (Prx). In the presence of reduced transition metal 
(Fe2+, Cu+), nitric oxide (NO) can be rapidly inactivated by reaction with O2- leading to the production 
of the strong oxidant peroxynitrite (ONOO-). Image from Fukai T, Ushio-Fukai M. Superoxide dismutases: 
Role in redox signaling, vascular function, and diseases. Antioxid Redox Signal. 2011;15(6):1583-1606 
 
ROS, especially hydrogen peroxide, can induce endothelial NO activity by 
inducing eNOS protein synthesis and activity156. This increase in activity results in more 
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NO to react with these ROS236. The most important defense mechanism at cellular level 
against O2- is the superoxide dismutase enzyme (SOD). This enzyme converts O2- into 
H2O2 with the help of certain metals like copper and manganese as a catalytic metal 
through oxidation reduction reactions236. H2O2 is then transformed to H2O by catalase, 
peroxiredoxins or glutathione peroxidases enzymes237. There are three isoforms of SOD 
that vary in location and genetic formation. 
SOD1 
The location of this enzyme is the cytoplasm of the cell238, 239. The chromosome 
that contains the genetic code for this isoform is chromosome 21, which is related to 
Down syndrome (Trisomy 21). Patients with down syndrome, therefore, have an extra 
copy of the SOD1 gene that shows increased activity240. The metal cofactors for this 
isoform of the enzyme are Cu++ and Zn++ and its half-life is 6-10minutes241. 
SOD2 
Located in the mitochondria, the main target of SOD2 is O2- that results from the 
electron transport chain242. The metal cofactor of SOD2 is Mn and it has a half-life of 5-6 
hours. Deficiency of this isoform leads to disturbances in mitochondrial function in 
addition to cardiomyopathies and degenerative diseases in mice that lead to death243.  
SOD3 
This isoform is usually located in the vascular extracellular space and on the 
surface of smooth muscle cells of the blood vessels, lung, uterus, kidney, and heart 
tissues244. Although it is produced by the vascular smooth muscle, it binds to the 
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extracellular surface of the endothelial cells245. The metal cofactors for this isoform are 
Cu++ and Zn++ and any abnormality in SOD3 can lead to ischemic heart disease in 
mice246.  
Endothelial nitric oxide synthase itself can take part in oxidative stress by 
generating superoxide anions instead of nitric oxide247,248 through a process called eNOS 
uncoupling that accompanies many medical conditions like diabetes, hypertension and 
atherosclerosis249. eNOS uncoupling can also result from activation of thromboxane 
receptors (Tpr) by thromboxane A2, which is an eicosanoid derived from arachidonic 
acid, is distributed in various tissue in the body and participates in many physiological 
processes like renal function, immunity, hemostasis, wound healing, vascular tone, as 
well as other inflammatory conditions250. The activation of Tpr by thromboxane A2 was 
found to increase the production of O2- by vascular smooth muscle cells leading to 
increased formation of (ONOO-) and eNOS uncoupling251. 
NO is considered an important mediator in many neurodegenerative diseases in 
the nervous tissue like Parkinson disease252, Alzheimer’s disease, amyotrophic lateral 
sclerosis253, Huntington chorea232, and stroke254. NO promotes neurodegeneration through 
fragmentation of intracellular organelles like mitochondria and the Golgi apparatus which 
are important in energy production and cellular mitosis resulting in stress and cell 
death255. NO also promotes neurodegeneration by disturbance of the mitochondrial 
respiratory chain through the inhibition of mitochondrial respiratory complex enzymes. 
Two main concepts are related to endothelial dysfunction and the failure of 
sufficient NO production to cause blood vessel relaxation including diabetic macro 
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vascular complications like neuropathy, nephropathy, retinopathy, and erectile 
dysfunction. Diabetic complications also include increased risk of stroke and ischemic 
heart disease as well as increased severity of these diseases256,257.   
The possible explanations of these complications include depletion of many 
intracellular antioxidant enzymes like glutathione peroxidase as a consequence of 
consumption of NADPH to NADP and reduction of NAD to NADH during the 
pathological reduction of glucose to sorbitol and oxidation of sorbitol to fructose in 
diabetic patients. Therefore the cells become prone to stress damage and nitrosative 
injury258,259. Also the increase of intracellular diacylglycerol as a result of increased 
protein kinase c isoforms reduce endothelial NO synthesis260.  Antioxidants like 
superoxide dismutase improve endothelium-dependent vasodilation in blood vessels from 
individuals with diabetes 261,262. The increase of intracellular glucose with diabetes 
increases the release of electrons from the tricarboxylic acid cycle. These liberated 
electrons increase the proton gradient of the mitochondria increasing the release of 
superoxide ions263. 
NO and Diabetes 
Normally, insulin stimulates the uptake of glucose by skeletal muscle and adipose 
tissues through tyrosine phosphorylation of insulin receptors on the cell surface. This 
leads to the phosphorylation of insulin receptor substrate-1 (IRS-1) and Shc264 resulting 
in the activation of two intracellular pathways:PI3 kinase (PI3K)-AKt, and 
Ras/Maf/MAP Kinase pathways265.  In the vasculature, activation of the PI3K pathway, 
leads to phosphorylation and activation of eNOS while activation of the Ras pathway 
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causes mitogenic effects as well as increased expression of the endothelial-derived 
vasoconstrictor endothelin-1265.  
In insulin resistance that accompanies certain clinical conditions like obesity, 
diabetes, and metabolic syndrome265, the balance between the two pathways is disturbed. 
Activation of the (PI3K)-AKt pathway is impaired leading to decreased NOS activity and 
NO bioavailability, therefore decreasing insulin dependent vasodilation266.  In contrast, 
the function of Ras pathway is usually preserved during insulin resistance resulting in 
endothelial dysfunction as endothelin-1 concentrations increase265. Interestingly, as a 
result of endothelial dysfunction vasoconstriction develops, disturbing glucose delivery to 
peripheral tissues by interfering with increased blood flow that would normally result 
from insulin-induced vasodilation267.  
In eNOS knock-out mouse models, (low availability of NO in blood vessels wall), 
blood pressure is 30% higher than in the wild type mice268. The absence of eNOS also 
augments the inotropic response of cardiac muscle and increased cardiac contractility. In 
contrast, nNOS gene deletion is associated with arrhythmia and left ventricular 
remodeling after infarction269. Moreover, eNOS knock-out mice have enlarged infarction 
areas in the brain and fail to preserve blood follow to the affected region with a 
prominent neurological deficit. In contrast nNOS knockout mice have smaller infarction 
areas suggesting that increased NO production in cerebral ischemia worsens the condition 
although the presence of NO is proposed to serve important physiological function during 
the normal conditions270. 
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Leptin and NO         
             Intravenous leptin administration is associated with an increase in plasma NO 
concentrations in a time- and dose-dependent manner in rat aortic vessels271. On the other 
hand, central administration of  leptin stimulates the sympathetic nervous system which 
increases the sympathetic outflow to blood vessels and the kidneys in rats272. Whereas 
this should increase blood pressure through vasoconstriction, under normal and healthy 
conditions, leptin creates a balance between the pressor effect caused by the sympathetic 
nervous system and the depressor response caused by NO272. 
Among the evidence that supports the idea that leptin mediates vasodilation 
through the NO pathway, Limbo et al273 demonstrated that the administration of leptin to 
a phenylephrine-constricted rat aortic ring resulted in vasorelaxation. This effect of leptin 
was abolished by either endothelial denudation of the aortic ring, administration of the 
nitric oxide synthase (NOS) inhibitor L-NAME (nitro L-arginine methyl ester), or by 
inhibiting soluble guanylate cyclase273.  
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Figure 10. Effects of leptin in the vascular wall of aortic vesselsl in human. In endothelial cells, leptin 
stimulates AMP-activated protein kinase (AMPK), which phosphorylates and activates protein kinase Akt. 
Phosphorylated Akt, in turn, phosphorylates endothelial nitric oxide synthase (eNOS), which generates 
nitric oxide (NO). NO activates soluble guanylate cyclase (sGC), which synthesizes cGMP in smooth 
muscle cells to induce vasorelaxation. Endothelial NOS may also be activated by insulin, which stimulates 
the phosphoinositide 3-kinase (PI3-K) pathway.leptin stimulates i NOS to produce NO causing 
vasorelaxation beside its role in EDHF which also results in vasorelaxation in leptin sensitive blood 
vessels.This effect is diminished in obese people and may contribute to hypertension. Image from Beltowski 
J. Leptin and the regulation of endothelial function in physiological and pathological conditions. Clin Exp 
Pharmacol Physiol. 2012;39(2):168-178.  
 
 Insulin stimulates insulin receptors on vascular endothelial cells resulting in 
phosphorylation of insulin receptor substrates (IRS1, IRS2) resulting in stimulation of the 
phosphoinositide 3-kinase (PI3K) pathway causing Akt to stimulate NO production from 
eNOS274. Leptin binding to its receptor activates the same signaling pathway in the 
endothelial cells of rats without stimulating insulin receptors275. Moreover, leptin 
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increases Akt phosphorylation and eNOS stimulation in aortic rings obtained from rats276 
through the Akt pathway in the endothelial cells without activation of PI3K. 
This information is important in understanding the development of hypertension 
in obese patients with hyperleptinemia as the anorectic effect of leptin in the 
hypothalamus is impaired while the sympathetic nervous system effect of leptin is over-
stimulated leading to the development of hypertension. Moreover, chronic 
hyperleptinemia, which accompanies leptin resistance is associated with the generation of 
ROS and oxidative stress also contributing to vascular pathologies277. 
Omega 3 
Omega 3 is a polyunsaturated fatty acid with a double bond c=c located at the 
carbon atom number 3 in the chain from the methyl end. This position of the double bond 
makes it unaffected by any metabolism and transformation processes that take place 
inside the body. This bond is also more energy stable, and any other compound 
synthesized from these fatty acids will be obtained from changes taking place at 
carboxylic acid end or from double bonds located in the middle of the chain278. 
 
Figure 11.The structure of omega 3 fatty acids. Image from www.louisville.earthsave.org 
 
51 
 
Omega 3 fatty acids include three types of fats that range from alpha linoleic acid 
which comes from plant source like flaxseed oil, eicosapentaenoic  acid (EPA), and 
doxosahexaenoic acid (DHA) which are mainly obtained from fish oil278. These fatty 
acids are considered essential fatty acids because the human body cannot synthesize 
them279. Therefore, they can only be obtained from dietary sources. In addition, humans 
have a limited ability to convert alpha lenolenic acid (ALA) which contains 18 carbon 
atoms in its structure and 3 double bonds by the process of elongation into EPA with 20 
carbon atoms and 5 double bonds and then into DHA that contains 22 carbon atoms and 6 
double bonds. In fact, studies showed that the rate of conversion of ALA to EPA  varies 
between 0.2% and 21% and that of ALA to DHA to varies between 0% and 9%280, 
although this ability is more efficient in women compared to men281. In these fatty acids 
the double bonds all lie in cis configuration, which means that the two hydrogen atoms lie 
on the same side of the bond282. 
Dietary source 
The adequate intake (AI) level of omega 3 is 1.6 grams /day for men and 1.1 
grams / day for women and the Acceptable Macronutrient Distribution Range (AMDR) is 
0.6%-1.2% of total energy278. However it is reported that median consumption of EPA + 
DHA by Americans is between of 0 and b1  g/d of ALA283. This can be explained by a 
general reduction in fish intake, increased consumption of domestically- raised fish in 
comparison to ocean fish, and less omega 3 fatty acids available in commercial foods 284. 
It is estimated that about $33.9 billion is spent annually on alternative medicine in 
the United States of America alone. Of this, $14.8 billion was spent on nutritional 
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supplements. Omega -3 supplements (including fish oils) were reported as the most 
common non vitamin / non mineral product taken by adults285. It is recommended by the 
FDA that an adult should consume about 3 grams, on average of DHA and EPA daily. 
The American Heart Association recommends that patients with ischemic heart disease 
should consume fish oil two times a week which may increase to one gram of fish oil 
daily following a myocardial infarction and up to 2-4 grams daily to lower triglyceride 
levels278. 
In addition to the effect of omega 3 in the cardiovascular system, omega 3 fatty 
acids show various health benefits by improving blood pressure control, alleviating 
symptoms of rheumatoid arthritis and depression, as well as attenuating the progression 
of Alzheimer’s disease286,287,288,289. In general, omega 3 plasma levels are negatively 
associated with BMI, WC (waist circumference) as well as HC (hip circumference) in 
healthy and obese subjects290. Bhagavathi et al291 showed that the combination of omega 
3 fatty acids with synthetic organoselenium ( 1,4-phenylene bis(methylene) 
selenocyanate(p-XSC) ) can help suppress colon cancer growth and induce apoptosis of 
tumor cells  and through inhibition of  COX-2 and iNOS activity in colon tumors. 
Fish and fish oil 
Fish are considered an important nutrient source of omega 3. Fish can be divided 
into lean fish that store fat in the form of triacylglycerol in the liver, and oily fish that 
store fat in form of triacylglycerol in the flesh292. Cold water oily fish like sardines , 
salmon , herring , and anchovies are important sources of omega 3 fatty acids, however , 
these fish do not synthesize omega 3 in their body, but instead acquire it from their food 
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(algae or plankton)293. These omega 3 fatty acids concentrated in fish are, accumulated 
with high quantities of antioxidants like iodide and selenium which protect omega 3 from 
peroxidation. However, there are some concerns about fish oil intake from some species 
of fish like swordfish, sharks, and albacore tuna due to the possibility of toxic 
contamination by mercury, and dioxin294. Other sources of omega 3 include flaxseeds, 
kiwifruit, black raspberry, nuts, soybeans, linseeds, mustard, and canola295.    
Omega 3 fatty acids are metabolized by cytochrome P450 (CYP450) enzymes to 
their metabolites (epoxyeicosatetraenoic acid (17, 18-EEQ) and hydroxyeicosapentaenoic 
acid (20-HEPE) for EPA) and (epoxydocosapentaenoic acid (19, 20-EDP) and 
hydroxydocosahexaenoic acid (22-HDoHE) for DHA)296. Aspirin-acetylated 
cyclooxygenase-2 (COX-2) and 5-lipoxygenase enzymes also convert EPA to 18S- and 
18R-resolvins E1 and E2297 and aspirin-acetylated COX-2 converts DHA to 17R-
resolvins D1–D4 and 17R- protectin D1, and by 5- and 15-lipoxygenase 17S-group of 
metabolites298,299. These metabolites vary in their biological activity in comparison to the 
parent omega 3 fatty acids. For example, DHA shows weaker potency in relaxation of 
constricted arterioles through the activation of large-conductance calcium-activated 
potassium (BKCa) channels in comparison to the metabolites of  cytochrome P450 
enzymes300, while EPA shows stronger effects in comparison to its metabolites from the 
same enzyme groups301. 
Polyunsaturated fatty acids, including omega 3 fatty acids, are affected by the 
influence of ROS that interact with PUFA in cell membrane or lipoproteins through a 
process of uncontrolled peroxidation. Malondialdehyde, one of the end products of this 
peroxidation, has adverse effects in the human body302. 
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Omega 3 intake is associated with increase concentrations of EPA and DHA in 
the phospholipids of the cell membrane that include structures such as 
phosphatidylcholine and phosphatidylserine303. This effect leads to decreased liberation 
of arachidonic acid from phospholipid that can be used by COX and lipoxygenase 
enzymes to produce the 2-series prostaglandins, and 4-series leukotrienes304. However, 
omega 3 in fish oil intake by normal subjects showed incorporation of omega 3 in 
platelets phospholipid decreasing platelets count and function305. Omega 3 fatty acids 
also take part in the formation of diacylglycerol, which is a lipid molecule that takes part 
in cell signaling and activation of protein kinase class c (PKC)306. 
In addition to their functions as a part of cell membrane phospholipids, omega 3 
act as ligands to various receptors like G-protein coupled receptors, GPR120, that are 
present in gastrointestinal epithelial cells and macrophages. Activation of this group of 
receptors will leads to the secretion of glucagon-like peptide-1 from epithelial cells307 and 
anti-inflammatory effects in macrophages and monocytes through the activation of 
(GPR120)308. and by activation of many nuclear receptors like retinoid-activated nuclear 
receptor ( RXRβ)285 and peroxisome proliferator-activated receptor (PPAR) which is 
responsible for gene activation and synthesis of adiponectin309, while inhibiting the 
activity of the transcription factor, nuclear factor kappa B (NFκB)310. 
Omega 3 and Cardiovascular System 
Omega 3 intake negatively affects mechanisms involved in the process of 
cardiovascular disease including atherosclerosis and factors that can eventually causes 
myocardial infarction and stroke311,312. These mechanisms include reduction in serum 
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triacylglycerol levels up to 30% following intake of 2 grams of fish oil daily313 and 
reduction in chemo-attractant, growth factor, and adhesion molecules314,315, which are 
important in enhancing leukocytes and smooth muscle migration in the inner layer of the 
blood vessels wall starting the process of vascular inflammation316. 
Omega 3 is effective at decreasing blood pressure in both normo and hypertensive 
subjects317 and affects vascular endothelium relaxation through promotion of NO 
production which will be discussed later. In addition to the effect on atherosclerosis, 
omega 3 show preventive effects against factors that lead to acute cardiovascular events 
like myocardial infarction and stroke. This effect is mediated by the anti-thrombotic 
effects of omega 3 to decrease the production of TXA2 (a strong platelet aggregator) and 
PGI3 by COX-2 from the arachidonic acid, that is released from the phospholipids in the 
cell membrane by the effect of phospholipase A2305,318. This effect is modulated through 
the incorporation of omega 3 into the cell membrane phospholipids by 
phosphatidylethanolamine instead of arachidonic acid and when released by 
phospholipase A2, it leads to the formation of PGI3 and TXA3 which reduce platelet 
aggregation318. 
Omega 3 show anti- arrhythmic properties through decreasing the electrical 
excitability and ion modulation in cardiomyocytes as a result of increased omega 3 
concentrations inside the phospholipid bilayer  of the cell membranes319. 
Omega 3 shows the ability to decrease infiltration of inflammatory cells into 
atherosclerotic plaques and to decrease the activity of cells already present inside the 
plaques320. In addition, omega 3 affect the expression of some adhesion molecules like 
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ICAM-1 (intercellular cell-adhesion molecule-1) and VCAM-1 (vascular cell adhesion 
molecule-1) on the surface of endothelial cells321. These molecules are glycoproteins 
synthesized in response to the raise in the inflammatory cytokines. They are expressed 
from activated endothelial cells and are released by proteolytic shedding from the surface 
of the cells. Adhesion molecules stimulate the adhesion of monocytes to the endothelium 
cells and the uptake of oxidized low density lipoproteins to form foam cells in the sub-
endothelial space thereby initiating atherosclerosis through the  inhibition of  NF-KĸB 
(nuclear factor kappa B transcription factor ) activation, which regulates the synthesis of 
inflammatory molecules and cytokines321. In addition, omega 3 decreases the production 
of chemo attractants like monocyte chemo attractants protein 1 (MCP-1) and platelet 
derived factor322, which lead to stabilization of plaques and prevent their rupture. 
The balance in intake between omega 3 and omega 6 fatty acids is considered an 
important determinant in cardiovascular health. A low ration of omega 3 to omega 6 is 
considered a potential risk factor for the cardiovascular system and a provoker for 
inflammation status in the body323. Therefore, it is important to have 1:4 of omega 3 and 
omega 6. However, it is concerning that this ratio is often up to 1:15 in developed 
countries323. 
Omega 3 and Diabetes 
The daily consumption of omega 3 is associated with low prevalence of type 2 
diabetes mellitus324. This can be explained by the fact that omega 3 is considered an 
important component of the phospholipid bilayer in the cell membrane structure. 
Therefore, omega 3 can affect the transduction of insulin signals through the cell 
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membrane324. In addition, omega 3 fatty acids are involved in controlling many genes 
related to glucose metabolism325. Omega 3 may also decreases insulin resistance through 
decreasing serum triglyceride and small dense lipoproteins326. Moreover, it was found 
that substituting short chain fatty acids with omega 3 fatty acids has a positive effect on 
insulin sensitivity and impaired glucose tests327. Ramel et al.327 also showed that 
consumption of 1.3 grams daily of fish oil for 8 weeks decreased fasting blood glucose 
and insulin resistance in overweight and obese participants. 
Atherosclerosis and coronary heart disease are among the long term complication 
of diabetes mellitus, and it was concluded that diabetic patients supplemented with EPA-
DHA, have lower fatal CHD rate and the incidence of CHD is decreased with increased 
omega 3 intake328, 329. 
Leptin and Omega 3 
In general, omega 3 intake leads to healthy weight and prevents abdominal 
adiposit 290 and omega 3 intake is associated with low body mass index and low waist and 
hip circumferences290. Supplementation of healthy subjects with omega 3 also results a 
significant decrease in fat mass without altering body weight330. In contrast, in obese or 
overweight diabetic women, omega 3 intake decreases both total fat mass (mainly truncal 
fat mass) and subcutaneous adipocyte diameter331. 
Serum leptin is negatively correlated with the level of dietary omega 3 
intake332,333 and leptin expression and concentration are decreased following intervention 
with fish oil and/or long-chain (n-3) PUFA334. Moreover, Perez et al334 demonstrated that 
omega 3 supplementation to rats gaining weight on continuous high energy diets can 
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actually increase leptin mRNA expression. Leptin secretion is also negatively correlated 
with glucose metabolism, a relationship that is not influenced by insulin334. Also, Pieke et 
al335 showed that serum leptin levels decreased in hypertriglyceridemic patients after 
dietary SFA had been replaced by marine n-3-PUFA and MUFA.This effect can be 
attributed to omega-3 PUFA accumulation in adipose tissue336, which may incorporate 
into the membrane phospholipid fraction and TG lipid droplets of adipocytes337. This 
causes an alteration in fat tissue endocrine activity, as well as prevents adipose tissue 
inflammation338 and adipose tissue matrix remodeling339. Moreover, leptin receptor 
(LEPR) polymorphisms associated with increased insulin resistance (a key feature of 
metabolic syndrome) are more evident in individuals with low plasma (n-3) or high 
plasma (n-6) PUFA340. 
 
Figure 12. Effect of omega 3on leptin and adipose cells. Image from Pieke B, von Eckardstein A, Gulbahce 
E, et al. Treatment of hypertriglyceridemia by two diets rich either in unsaturated fatty acids or in 
carbohydrates: Effects on lipoprotein subclasses, lipolytic enzymes, lipid transfer proteins, insulin and 
leptin. Int J Obes Relat Metab Disord. 2000;24(10):1286-1296. 
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Omega 3 and NO 
NO synthesis in the endothelium of blood vessels is affected by the quantity and 
composition of fatty acid intake in the diet. Omega 3 have been shown to increase 
endothelial NO synthase activity in aortic rings through the induction of calcium 
mobilization and calmodulin system which in turn increases the NO production and its 
vasorelaxant activity in endothelial cells341. These effects are in addition to the 
translocation of  eNOS from specialized plasmalemmal membrane micro domains called 
caveolin to the cytoplasm following mechanical stimuli 341. Moreover, Stebbins et al342 
showed that long term intake of DHA will increases the expression of certain proteins 
like Akt kinase and heat shock proteins 90 that cause an increase in eNOS activity in 
response to shear stress or endothelial growth factor. This enhanced enzyme activity 
increases NO production up to 3- folds343. However, diets high in long chain fatty acids 
increase oxidative stress and decrease NO production in the endothelial cells even in the 
presence of healthy levels of antioxidants344. 
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CHAPTER 3 
METHODS 
This study is a secondary analysis of samples collected during a previous study 
conducted by Megan Gutierrez and Bianca Teran as a part of  their master’s thesis while 
attending Arizona State University in 2013 (Fish oil supplements and symptoms of the 
common cold in healthy young women , Omega-3 supplementation and body weight in 
healthy young women). An informed written consent was obtained from all participants, 
and the Institutional Review Board at Arizona State University approved the study.  
The subjects in the original study were healthy, normal weight women between 
the ages of 18-38 years from at Arizona State University. Subjects were recruited through 
emails using the Arizona State University listserv. Eligibility of those that responded to 
the email was determined based on diet, physical activity, smoking habits, brief medical 
history, and self-reported BMI. Exclusion criteria included regular smoking (use of >10 
cigarettes per day), BMI >30 or <18.5, regular intake of omega-3 or fish oil supplements, 
vegetarian dietary patterns (exclusion of all fish, meat, and poultry from the diet), regular 
consumption of one or more 3.5oz servings of fish per week, and/or use of prescription 
medications that may have a potential effect on body weight or affect the inflammatory 
state (such as corticosteroids or non-steroidal anti-inflammatory drugs). Women were 
also excluded if they were pregnant or lactating, as well as competing and/or training 
athletes, or on birth control for less than 3 months. Furthermore, subjects with any 
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unresolved health issues were not included in the study. Finally, anyone who has had the 
seasonal flu shot was excluded because of an accompanying study.  
 Subjects who were deemed eligible were contacted for the first screening 
interview. During this visit participants completed a written consent form, completed a 
brief medical history questionnaire, and a validated omega-3 fatty acid food frequency 
questionnaire (FFQ). Anthropometric measurements, including weight, height, and 
percent body fat, were also measured at this visit. Height and weight were measured 
using a stadiometer and calibrated scale. BMI and percent body fat were measured using 
a bioelectrical impedance scale (Tanita). 
Qualifying subjects entered the 8-week trial and were randomly assigned to either 
the experimental (fish oil, FISH) or control (placebo, CON) group. Random assignments 
to groups were performed by a coin toss. 
During the second visit, estimated dietary and calorie intake were obtained by a 
24 hour recall and participants received supplements based on double-blind procedures to 
prevent bias. Participants received either placebo (Puritan’s Pride brand, coconut oil soft 
gels, 1000mg each) or fish oil capsules (Energy First brand, USP-certified fish oil soft 
gels, 400mg EPA + 200mg DHA/capsule), which were similarly-sized gel capsules. 
Participants were instructed to ingest one capsule in the morning, preferably with food, 
and check off each day that a capsule was taken on a provided calendar. Participants were 
also given booklets containing validated Godin Leisure-Time Exercise questionnaires to 
complete weekly, and were instructed to document the use of alcohol, cigarettes, 
medications, and supplements each day of the trial period. All questionnaires were 
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explained to the subjects, and a trial-run was completed. Height, weight, BMI, and 
percent body fat measurements were also taken during this “baseline” visit (using a 
stadiometer and a bioelectrical impedance scale, Tanita) and a fasting blood sample was 
collected. 
Measurements taken weeks 4 and 8 included body weight, percent body fat, and 
BMI measurements. Unused capsules from the previous weeks were returned during 
these visits using a double-blind procedure, and remaining study materials (booklets 
containing physical activity log and capsules for weeks 5-8) were distributed during the 
week 4 visit. A final 24-hour dietary recall and fasting blood sample were also collected 
during the final visit (week 8). 
Compliance to capsule administration was monitored through capsule counts at 
weeks 4 and 8. Biweekly emails from a blind master list were also sent to all subjects to 
check for compliance to the study protocol. 
A total of 35 subjects were enrolled in the study, allowing for 18 subjects to be in 
the fish oil group (FISH) and 17 subjects in the coconut oil placebo group (CON). 
However, a total of 9 subjects dropped out throughout the study, leaving 13 subjects in 
each group (for a total of 26 subjects) that completed the study. 
Laboratory analyses 
Plasma leptin concentrations were measured using a commercially available kit 
(eBioscience, Cat. BMS2039INST) according to the manufacturer's directions (see 
Appendix A). However, since there was a 20% possibility for measuring error with using 
this kit, we used leptin measurements from the original study in the statistical analysis.   
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Plasma nitrate and nitrite concentrations were measured on samples collected at 
baseline and at week 8 of study using a commercially available kit (Cayman Chemical 
Company, Cat. 780001) following the manufacturer's methods (Appendix B). 
Plasma superoxide dismutase activity was measured at baseline and at the end of 
the study (week 8) according to the manufacturer's protocol (Appendix C) using a 
commercially available kit (Cayman Chemical Company, Cat. 706002). 
Statistical Analyses 
The data were analyzed using SPSS Statistical Software. Mann-Whitney U test 
was used to compare leptin, NO, and super oxide dismutase levels at the beginning, and 
end of the 8 week study between the omega 3 and control groups. Spearman correlations 
were used to determine if there was an association between serum leptin and NO 
concentrations. Mean, median, and standard deviations were measured for all variables.  
(p-values of ≤0.05) were considered statistically significant. 
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CHAPTER 4 
RESULTS  
Twenty six subjects (13 in fish oil group and 13 in control group) completed the 
study. All baseline data are presented in Table 1. Mean participant age at baseline was 
24±5 years for the fish oil group, while it was 23±6 years for the control group. Mean 
BMI at baseline was 23.2 ±2.9 for fish oil group and 24.2±3.3 for control. Baseline mass 
weight for the fish oil group was 140.7±22.0 and 147.6±23 pounds for the control group.  
Percent body fat at baseline for the fish oil group was 28.4±7.0 and 30.1±6.6 for control 
group. 
Mean leptin concentrations at baseline were 13.8±8 and 16.2±7.5 ng/ml for the 
fish oil group and control groups, respectively. Mean concentrations of NO in the fish oil 
group was 11.1±8.2 µM in comparison to 10.1±3.0 µM in control group. The mean level 
for SOD at baseline for fish oil group showed 3.30±1.8 U/ml, while it was at 3.05±1.3 
U/ml in the control group. 
Table1.  Subject characteristics at baseline 
 FISH OIL    RANGE CONTROL RANGE *P VALUE 
Subjects , n 13  13   
AGE,Y 24±6    18-38 23±6 18-38 0.362 
BMI 23.2±2.9 19.5-29.9 24.2±3.29 18.8-29.6 0.362 
WEIGHT,LB 141±22 108-185 148±23 111-199 0.545 
BF%(body fat 
percent) 
28.4±7.0 15.0-38.9 30.1±6.6 19-39.9 0.687 
LEPTIN 13.8±8.6 3.35-27.9 16.2±7.5 3.44-29.3 0.479 
NO µM 11.1±8.2 4.90-37 10.1±3.0 5.50-17.1 0.614 
SOD U/ml 3.30±1.8 2.15-9.15 3.05±1.2 2.01-6.90 0.614 
 
*p-value represents Mann-Whitney U 
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All data for participants at the end of the study (week 8) are presented in Table 2). 
At the end of the study mean BMI for fish oil group was 23.1±3.1 in comparison to 24±3 
in control group. The mean body mass for fish oil group at the end of the study was 
140±23 while it was 147±23 pounds for those in control group. The mean percent body 
fat was 29.04±6.9 for fish oil group and 30.8±6.3 for control group. 
Mean leptin concentrations in the fish oil group at the end of the study was 
15.3±9.0 in comparison to 17.2±8.24 ng/ml for the control group at the end of the study, 
while mean NO levels at the end of 8 weeks for fish oil group and control group were 
10.1±5.9 µM and 11.1±6.0 µM, respectively. Lastly, mean SOD levels for the fish oil 
group were 3.53±1.6 U/ml in comparison to 3.07±1.0 U/ml for control group at the end of 
the study (8 weeks). 
Table2.  Subject characteristics at week 8 
 FISH OIL RANGE CONTROL RANGE P VALUE* 
Subjects , n 13  13   
BMI 23.1±3 19.3-30.4 24.0±3.3 18.4-28.9 0.362 
WEIGHT,LB 140±2 108-188 146±23 115-199 0.448 
BF 29.0±6.9 15.0-39.9 30.8±6 19.9-40 0.687 
LEPTIN 15.3±9.08 3.59-33.0 17.2±8.2 4.10-31.1 0.687 
NO µM 10.1±5.9 5.29-28.8 11.1±6.0 4.98-21 0.960 
SOD U/ml 3.53±1.6 2.73-8.70 3.07±0.96 2.07-5.69 0.287 
*p-value represents Mann-Whitney U 
The percent change in data from baseline to week 8 is presented in Table 3. The 
percent change of leptin showed an increase in both groups at the end of the study. 
Although not significant, the fish oil group appeared to increase more than the controls 
(15.3±31.9 for fish oil group, 7.83±27 for control group; p value was 0.763). The percent 
change in SOD for the fish oil group was 11.94±20.94 in comparison to control group 
11.8±53.9. However these changes were not significant (p=0.362). NO percent change 
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was -1.97±22 in fish oil group while it was 11.8±53.9 in the control group. This change 
was not significant (p=0.960). 
 
Table 3.  Percent change in plasma leptin, NO, SOD after 8 weeks of fish oil or placebo 
supplementation 
 Fish Oil Control P-value* 
Leptin,  15.30±31.88 7.83±26.8 0.763 
SOD 11.94±20.94 3.79±19.14 0.362 
NO -1.97±22.57 11.78±53.86 0.960 
*p-value represents Mann-Whitney U 
The Pearson correlation co-efficient between the percent change of both leptin 
and NO was r2= -0.251. 
 
Figure 13.  Correlation of change in leptin with change in NO. The correlation co-efficient was r2=-0.251.   
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The Pearson correlation co-efficient between percent change in leptin and total 
calories intake was  r2 = -0.039 
 
 
Figure 14. Correlation of percent change in leptin and the percent change in total caloric intake. The 
correlation co-efficient was r2=-0.039. 
 
The Pearson correlation co-efficient between percent change of leptin and percent 
change in total fat intake was r2 = 0.156 and the Pearson correlation co-efficient between 
percent change of leptin and percent change in total calories from fat intake was r2 = 
0.231 
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   Figure 15. Correlation of percent change in leptin with the percent change in fat intake. The correlation 
co-efficient is r2=0.156. 
 
 
 
 
 
Figure 16. Correlation of percent change in leptin with percent change in caloric intake from fat. The 
correlation co-efficient is r2=0.231. 
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CHAPTER 5 
DISCUSSION 
 
Subjects showed no significant difference in their descriptive characteristics at 
baseline and at the end of the study (Tables 1, 2). Both the omega 3 group and control 
group showed no marked difference in their weight or body fat percent and although not 
significant, BMI tended to increase in both groups. Leptin hormone showed a slight 
increase at the end of the study in comparison to its level in both groups at baseline, a 
similar pattern was evident in NO in both groups, while SOD showed no marked 
difference between week 0 and week 8 in either group. 
The percent change in leptin between week 0 and week 8 increased in both 
groups, although the standard deviation was high. Leptin tended to increase more in the 
omega 3 group in compare to control (Table 3), although the change in leptin was not 
significant. These findings are in contrast to prior studies that have shown decrease in 
leptin following regular intake of 300-600 mg of omega 3345 as leptin and omega 3 are 
negatively correlated332. 
SOD percent change in both groups was increased with a marked high standard 
deviation in both groups but the change, although not significant, was greater in the 
omega 3 group (Table 3). These findings are similar to prior studies that have shown an 
increase in SOD activity following omega 3 intake15 and a significant increase in SOD 
levels346. 
  Percent change in NO in the omega 3 group declined by the end of the study 
while it increased in the control group; however the standard deviation was large in both 
groups (Table 3). Other studies have shown that omega 3 supplementation increases the 
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production of NO and NOS activity in blood vessels341.  However high supplementation 
of long chain fatty acids (11.5 % of total energy intake for 4 weeks) can lead to increased 
oxidative stress and eventually decreased availability of NO344. In contrast to the 
hypothesis that leptin and NO would be positively correlated 271, a weak negative 
association was found in the current study (r2= -0.251). 
In addition the Pearson correlation co-efficient between percent change in leptin 
level with the percent change of fat intake was weakly positive (r2 = 0.156). The percent 
change of total caloric intake was also weakly negative (r2 = -0.039) and total caloric 
intake from fat was weakly positive (r2 = 0.231). Our findings were similar to a prior 
study that showed a positive association between leptin and total caloric intake from 
fat347. 
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CHAPTER 6 
CONCLUSION 
In conclusion, the results of the study accepted the first null hypothesis as leptin 
hormone concentrations did not change significantly following 8 weeks of omega 3 
supplementation (600 mg/daily) in healthy adult female subjects. Although the omega 3 
and control groups appeared to show an increase in leptin, this increase did not reach 
significant levels. Leptin levels at the baseline of this study were within normal levels for 
healthy non obese subjects and leptin level tend to increase with increasing body fat 
mass. Therefore, low dose of omega 3 on healthy subjects in this study did not show 
significant results. 
In this study NO levels did not significantly change following the same 
intervention protocol. Therefore the second null hypothesis can be accepted. The third 
null hypothesis was also accepted in this study as SOD levels did not change significantly 
following the omega 3 treatments. Similarly, the fourth null hypothesis was accepted 
since the study did not find a significant association between leptin and NO levels. 
The negative findings in this study may be due to the fact that the subjects who 
participated in the study were healthy and not obese nor did they report any health 
conditions known to raise oxidative stress or inflammation.  Since leptin is an adipose 
derived hormone, normal weight individuals would be expected to have lower levels than 
obese individuals. In contrast to observations in rabbits16, omega 3 supplementation did 
not appear to upregulate leptin expression resulting in greater release in the current 
protocol.  
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Understanding the mechanism of weight control in the body and the elements that 
participate in this process like leptin hormone is very important in the management and 
prevention of a common health concern like obesity. The concept of endothelial 
dysfunction and its relation to cardiovascular disease can be explored further and clarified 
through better understanding of the function of NO and SOD enzyme in vascular function 
and oxidative stress. 
Omega 3 is an important poly unsaturated fatty acid that has protective effects in 
the cardiovascular system and can decrease fat mass in the body. A larger sample size 
that includes healthy males or overweight male and female subjects may have resulted in 
different outcomes since obesity and overweight are associated with increase the level of 
inflammation and oxidative stress and associated with marked increase in leptin levels. 
Moreover, a higher dose of omega 3 fatty acids may have elicited greater effects than 
those observed in the prior study. Future studies in this area should therefore include 
male subjects as well as overweight subjects administered larger doses of fish oil that are 
equivalent to three or more servings per week as opposed to the two servings 
implemented in the current study. The importance of gender cannot be underestimated 
since estrogen has protective effects in the vasculature of females that may have masked 
any further protective effects of the fish oil. 
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APPENDIX A 
LEPTIN ASSAY PROTOCOL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 
 
Principles of the Test 
An anti-human Leptin coating antibody is adsorbed onto microwells. Human 
Leptin present in the sample or standard binds to antibodies adsorbed to the microwells; a 
biotin-conjugated anti-human Leptin antibody binds to human Leptin captured by the 
first antibody. Streptavidin-HRP binds to the biotin conjugated anti-human Leptin. 
 
Following incubation unbound biotin conjugated antihuman Leptin and 
Streptavidin-HRP is removed during a wash step, and substrate solution reactive with 
HRP is added to the wells. 
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A coloured product is formed in proportion to the amount of soluble human 
Leptin present in the sample. The reaction is terminated by addition of acid and 
absorbance is measured at 450 nm. A standard curve is prepared from 7 human Leptin 
standard dilutions and human Leptin sample concentration determined 
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Reagents Provided 
1 aluminium pouch with a Microwell Plate coated with monoclonal antibody to 
human Leptin, Biotin-Conjugate (anti-human Leptin monoclonal antibody), Streptavidin-
HRP and Assay Buffer, lyophilized 
2 aluminium pouches with a human Leptin Standard curve 
(coloured) 
1 bottle (25 ml) Wash Buffer Concentrate 20x 
(phosphate-buffered saline with 1% Tween 20) 
1 vial (5 ml) Assay Buffer Concentrate 20x 
(Use when an external predilution of the samples is needed) 
1 vial (15 ml) Substrate Solution (tetramethyl-benzidine) 
1 vial (15 ml) Stop Solution (1M Phosphoric acid) 
2 Adhesive Films 
Storage Instructions 
Store ELISA plate and Standard curves or whole kit at -20°C. The plate and the 
standard curves can also be removed, stored at -20°C, remaining kit reagents can be 
stored between 2° and 8°C. Expiry of the kit and reagents is stated on labels. The expiry 
of the kit components can only be guaranteed if the components are stored properly, and 
if, in case of repeated use of one 
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component, the reagent is not contaminated by the first handling. 
Specimen Collection 
Serum and plasma (EDTA, citrate, heparinized) were tested with this assay. Other 
biological samples might be suitable for use in the assay. Remove serum or plasma from 
the clot or cells as soon as possible after clotting and separation. 
Samples containing a visible precipitate must be clarified prior to use in the assay. 
Do not use grossly hemolyzed or lipemic specimens. Samples must be stored frozen at -
20°C to avoid loss of bioactive human Leptin. If samples are to be run within 24 hours, 
they may be stored at 2° to 8°C (for sample stability refer to 13). Avoid repeated freeze-
thaw cycles. Prior to assay, the frozen sample should be brought to room temperature 
slowly and mixed gently. 
Materials Required But Not Provided 
 5 ml and 10 ml graduated pipettes 
 5 µl to 1000 µl adjustable single channel micropipettes with disposable tips 
 adjustable multichannel micropipettes (for volumes between 50 µl and 500 µl) 
with disposable tips 
 Multichannel micropipette reservoir 
 Beakers, flasks, cylinders necessary for preparation of reagents 
 Device for delivery of wash solution (multichannel wash bottle or automatic 
wash system) 
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 Microwell strip reader capable of reading at 450 nm (620 nm as optional 
reference wave length) 
 Glass-distilled or deionized water 
 Statistical calculator with program to perform linear regression analysis 
Precautions for Use 
 All chemicals should be considered as potentially hazardous. We therefore 
recommend that this product is handled only by those persons who have been 
trained in laboratory techniques and that it is used in accordance with the 
principles of good laboratory practice. Wear suitable protective clothing such as 
laboratory overalls, safety glasses and gloves. Care should be taken to avoid 
contact with skin or eyes. In the case of contact with skin or eyes wash 
immediately with water. See material safety data sheet(s) and/or safety 
statements(s) for specific advice. 
 Reagents are intended for research use only and are not for use in diagnostic or 
therapeutic procedures. 
 Do not mix or substitute reagents with those from other lots or other sources. 
 Do not use kit reagents beyond expiration date on label. 
 Do not expose kit reagents to strong light during storage or incubation. 
 Do not pipette by mouth. 
 Do not eat or smoke in areas where kit reagents or samples are handled. 
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 Avoid contact of skin or mucous membranes with kit reagents or specimens. 
 Rubber or disposable latex gloves should be worn while handling kit reagents or 
specimens. 
 Avoid contact of substrate solution with oxidizing agents and metal. 
 Avoid splashing or generation of aerosols. 
 In order to avoid microbial contamination or cross-contamination of reagents or 
specimens which may invalidate the test use disposable pipette tips and/or 
pipettes. 
 Use clean, dedicated reagent trays for dispensing substrate reagent. 
 Glass-distilled water or deionized water must be used for reagent preparation. 
 Substrate solution must be at room temperature prior to use. 
 Decontaminate and dispose specimens and all potentially contaminated materials 
as they could contain infectious agents. The preferred method of decontamination 
is autoclaving for a minimum of 1 hour at 121.5°C. 
 Liquid wastes not containing acid and neutralized waste may be mixed with 
sodium hypochlorite in volumes such that the final mixture contains 1.0% sodium 
hypochlorite. Allow 30 minutes for effective decontamination. Liquid waste 
containing acid must be neutralized prior to the addition of sodium hypochlorite. 
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Preparation of Reagents and Samples 
Buffer concentrates should be brought to room temperature and diluted before 
starting the test procedure. If crystals have formed in buffer concentrates, warm them 
gently until crystals have completely 
Wash Buffer (1x) 
Pour entire contents (25 ml) of the Wash Buffer Concentrate (20x) into a clean 
500 ml graduated cylinder. Bring to final volume to 500 ml with glass-distilled or 
deionized water. Mix gently to avoid foaming. Transfer to a clean wash bottle and store 
at 2° to 25°C. Please note that Wash Buffer (1x) is stable for 30 days. 
Assay Buffer 
Pour the entire contents (5ml) of the Assay Buffer Concentrate into a clean 100 
ml graduated cylinder. Bring to final volume of 100 ml with distilled water. Mix gently 
Test Protocol 
 Use plate immediately after removal from -20°C! 
 Do not wait until pellets have completely dissolved before applying samples - the 
binding reaction in the standard strips starts immediately after addition of water! 
 Do not try to dissolve pellets by pipetting up and down in the wells - some parts 
of the pellet could stick to the tip creatinghigh variation of results. 
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 Perform the washing step with at least 400 µl of washing buffer as stated in the 
manual or fill the wells completely – otherwise any pellet residues sticking to the 
rim of the well will not be removed and create high variation of results. 
 Allow the washing buffer to sit in the wells for a few seconds before aspiration. 
 Remove covers of the standard strips carefully so that all the lyophilized pellets 
remain in the wells 
a. Prepare your samples before starting with the test procedure. Dilute serum or 
plasma samples 1:25 with Assay Buffer according to the following dilution 
scheme: 10 µl sample + 240 µl Assay Buffer 
b. Determine the number of Microwell Strips required to test the desired number 
of samples plus Microwell Strips for blanks and standards (coloured). Each 
sample, standard and blank should be assayed in duplicate. Remove extra 
Microwell Strips from holder and store in foil bag with the desiccant provided at -
20°C sealed tightly. Place Microwell Strips containing the standard curve in 
position A1/A2 to H1/H2 (see Table 1). 
c. Add distilled water to all standard and blank wells as indicated on the label of 
the standard strips (A1, A2 to H1, H2). 
d. Add 100 µl of distilled water to the sample wells 
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Table depicting an example of the arrangement of blanks, standards and samples in the 
microwell strips: 
 
e. Add 50 µl of each 1:25 prediluted sample, in duplicate, to the designated wells 
and mix the contents. 
f. Cover with an adhesive film and incubate at room temperature (18ºC to 25ºC) 
for 3 hours, if available on a microplate shaker at 400 rpm. 
g. Remove adhesive film and empty wells. Wash the microwell strips 6 times with 
approximately 400 µl Wash Buffer per well with thorough aspiration of microwell 
contents between washes. Allow the Wash Buffer to sit in the wells for about 10 – 
15 seconds before aspiration. Take care not to scratch the surface of the 
microwells. After the last wash, tap microwell strips on absorbent pad or paper 
towel to remove excess Wash Buffer. Use the microwell strips immediately after 
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washing or place upside down on a wet absorbent paper for no longer than 15 
minutes. Do not allow wells to dry. 
h. Pipette 100 µl of TMB Substrate Solution to all wells, including the blank 
wells. 
i. Incubate the microwell strips at room temperature (18° to 25°C) for about 10 
min. Avoid direct exposure to intense light. The colour development on the plate 
should be monitored and the substrate reaction stopped (see next point of this 
protocol) before positive wells are no longer properly recordable. Determination 
of the ideal time period for colour development has to be done individually for 
each assay. It is recommended to add the Stop Solution when the highest standard 
has developed a dark blue colour. Alternatively the colour development can be 
monitored by the ELISA reader at 620 nm. The substrate reaction should be 
stopped as soon as Standard 1 has reached an OD of 0.9 – 0.95. 
j. Stop the enzyme reaction by quickly pipetting 100 µl of Stop Solution into each 
well, including the blank wells. It is important that the Stop Solution is spread 
quickly and uniformly throughout the microwells to completely inactivate the 
enzyme. Results must be read immediately after the Stop Solution is added or 
within one hour if the microwell strips are stored at 2 - 8°C in the dark. 
k. Read absorbance of each microwell on a spectro-photometer using 450 nm as 
the primary wave length (optionally 620 nm as the reference wave length; 610 nm 
to 650 nm is acceptable). Blank the plate reader according to the manufacturer's 
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instructions by using the blank wells. Determine the absorbance of both the 
samples and the human Leptin standards. 
Note: In case of incubation without shaking the obtained O.D. values may be lower than 
indicated below. Nevertheless the results are still valid 
Calculation of Results 
 Calculate the average absorbance values for each set of duplicate standards and 
samples. Duplicates should be within 20 per cent of the mean. 
 Create a standard curve by plotting the mean absorbance for each standard 
concentration on the ordinate against the human Leptin concentration on the 
abscissa. Draw a best fit curve through the points of the graph (a 5-parameter 
curve fit is recommended). 
 To determine the concentration of circulating human Leptin for each sample, first 
find the mean absorbance value on the ordinate and extend a horizontal line to the 
standard curve. At the point of intersection, extend a vertical line to the abscissa 
and read the corresponding human Leptin concentration. 
 *Samples have been diluted 1:50, thus the concentration read from the standard 
curve must be multiplied by the dilution factor (x 50). 
 Calculation of samples with a concentration exceeding standard 1 may result in 
incorrect, low human Leptin levels. Such samples require further external 
predilution according to expected human Leptin values with Assay Buffer (1x) in 
order to precisely quantitate the actual human Leptin level. 
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 It is suggested that each testing facility establishes a control sample of known 
human Leptin concentration and runs this additional control with each assay. If 
the values obtained are not within the expected range of the control, the assay 
results may be invalid. 
 A representative standard curve is shown in Figure 4. This curve cannot be used 
to derive test results. Every laboratory must prepare a standard curve for each 
group of microwell strips assayed. 
* N.B: There is a common dilution factor for samples due to the conjugate which must 
then be included in the calculation. The samples contribute 100 µl to the final volume per 
well. These 100 µl are composed of 50 µl of Sample Diluent plus 50 µl of the 1:25 
prediluted sample. This is a 1:50 dilution. The remaining 50 µl to give 150 µl are due to 
the addition of 50 µl conjugate to all wells. 50 µl Sample Diluent and 50 µl conjugate 
results in 100 µl reconstitution volume, addition of 50 µl 1:25 prediluted sample (50 µl + 
50 µl 1:25 prediluted sample = 1:50 dilution). 
Representative standard curve for human Leptin Instant ELISA. Human Leptin 
was diluted in serial 2-fold steps in Assay Buffer. Each symbol represents the mean of 3 
parallel titrations. Do not use this standard curve to derive test results. A standard curve 
must be run for each group of microwell strips assayed. 
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Typical data using the human Leptin INSTANT ELISA. Measuring wavelength: 450 nm. 
Reference wavelength: 620 nm. 
 
The OD values of the standard curve may vary according to the conditions of 
assay performance (e.g. operator, pipetting technique, washing technique or temperature 
113 
 
effects). Furthermore shelf life of the kit may affect enzymatic activity and thus colour 
intensity. Values measured are still valid 
Limitations 
 Since exact conditions may vary from assay to assay, a standard curve must be 
established for every run. 
 Bacterial or fungal contamination of either screen samples or reagents or cross-
contamination between reagents may cause erroneous results. 
 Disposable pipette tips, flasks or glassware are preferred, reusable glassware 
must be washed and thoroughly rinsed of all detergents before use. 
 Improper or insufficient washing at any stage of the procedure will result in 
either false positive or false negative results. Empty wells completely before 
dispensing fresh wash solution, fill with Wash Buffer as indicated for each wash 
cycle and do not allow wells to sit uncovered or dry for extended periods. 
 The use of radioimmunotherapy has significantly increased the number of 
patients with human anti-mouse IgG antibodies (HAMA). HAMA may interfere 
with assays utilizing murine monoclonal antibodies leading to both false positive 
and false negative results. Serum samples containing antibodies to murine 
immunoglobulins can still be analysed in such assays when murine 
immunoglobulins (serum, ascitic fluid, or monoclonal antibodies of irrelevant 
specificity) are added to the sample 
Performance Characteristics 
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 Sensitivity 
The limit of detection of human Leptin defined as the analyte concentration 
resulting in an absorbance significantly higher than that of the dilution medium (mean 
plus 2 standard deviations) was determined to be 20 pg/ml (mean of 6 independent 
assays). 
Reproducibility 
Intra-assay: Reproducibility within the assay was evaluated in 3 independent 
experiments. Each assay was carried out with 6 replicates of 6 serum samples containing 
different natural levels of human Leptin. 2 standard curves were run on each plate. Data 
below show the mean human Leptin concentration and the coefficient of variation for 
each sample (see Table 3). The calculated overall intra-assay coefficient of variation was 
5.7%. 
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The mean human Leptin concentration and the coefficient of variation for each 
sample: 
 
Inter-assay:Assay to assay reproducibility within one laboratory was evaluated in 3 
independent experiments. Each assay was carried out with 6 replicates of 6 serum 
samples containing different concentrations of human Leptin. 2 standard curves were run 
on each plate. Data below show the mean human Leptin concentration and the coefficient 
of variation calculated on 18 determinations of each sample (see Table 4). The calculated 
overall inter-assay coefficient of variation was 6.9%. 
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The mean human Leptin concentration and the coefficient of variation of each 
sample 
 
Spike Recovery:The spike recovery was evaluated by spiking 2 levels of human Leptin 
into samples. Recoveries were determined in 4 independent experiments with 6 replicates 
each. The amount of endogenous human Leptin in unspiked samples was substracted 
from the spike values. Recovery ranged from 42% to 129% with an overall mean 
recovery of 86% (see Table 5). 
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Dilution Parallelism: Serum and plasma samples (4 samples of each sample matrix) 
with different levels of human Leptin were analysed at serial 2 fold dilutions with 4 
replicates each. The recovery ranged between 87% and 92% with an overall recovery of 
90% (see Table 6). 
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Sample Stability 
Freeze-Thaw Stability: Aliquots of serum samples (unspiked or spiked) were stored at -
20°C and thawed 5 times, and the human Leptin levels determined. There was no 
significant loss of human Leptin immunoreactivity detected by freezing and thawing 
Storage Stability: Aliquots of serum samples (spiked or unspiked) were stored at -20°C, 
2- 8°C, room temperature (RT) and at 37°C, and the human Leptin level determined after 
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24 h. There was no significant loss of human Leptin immunoreactivity detected during 
storage under above conditions 
Specificity: The assay detects both natural and recombinant human Leptin. The 
interference of circulating factors of the immune syteme was evaluated by spiking these 
proteins at physiologically relevant concentrations into positive serum. There was no 
crossreactivity detected 
Expected Values 
A panel of 40 sera samples from randomly selected apparently healthy donors 
(males and females) was tested for human Leptin. The detected human Leptin levels 
ranged between 797 and 508072 pg /ml with a mean level of 12991 pg/ml. The levels 
measured may vary with the sample collection used. For detected human Leptin levels 
see Table 8. 
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APPENDIX B 
NITRIC OXIDE ASSAY PROTOCOL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
121 
 
ABOUT THIS ASSAY 
Caymans nitrate/nitrite colorimetric assay kit provides an accurate and convenient 
method for measurement of total nitrate/nitrite concentration in a simple two way step 
process . the first step is the conversion of nitrate to nitrite utilizing nitrate into a deep 
purple azo compound . photometric measurement of the absorbance due to this azo 
chromophore accurately determines NO2 concentration . 
 
NADPH is an essential cofactor for the function of the NOS enzyme. 
Unfortunately, NADPH interferes with chemistry of the Griess reagents , which are the 
most commonly used reagents for nitrite detection . One way to prevent this interference 
is to use small amounts of NADPH in conjunction with a catalytic system for recycling 
spent NADP+ back to NADPH. This is system used in this nitrate/nitrite colorimetric 
assay kit. It works well for the analysis of nitrate and nitrite in fluids such as plasma and 
urine , and is also available in a highly sensitive fluorometric version (item No.780051) 
for the detection of low levels of nitrite . However, it cannot be used to analyze nitrate 
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and nitrite from an in vitro assay of NOS in which excess NADPH has been added . for 
these assays a second method (LDH method ) is utilized and is available from Cayman in 
a 96 well plate format (item 760871).  
PRE-ASSAY PREPARATION  
1-NITRATE/NITRITE ASSAY BUFFER (ITEM NO. 780022) 
 Is obtained by diluting the contents of the assay buffer vial to 100 ml with 
ultrapure water (milli-Q or equivalent), 1:2 ratio. This assay buffer should be used for 
dilution of samples as needed prior to assay, the buffer will be stable for approximately 
two months at 4°C. 
2-NITRATE REDUCTASE ENZYME PREPARATION (ITEM NO. 780010) 
 Through reconstitute the contents of the vial with 1.2 ml of assay buffer, and 
keeping it on ice during use. Store at -20°C when not in use. Freezing and thawing of this 
solution should be limited to one time. 
3-NITRATE REDUCTASE COFACTOR PREPARATION (ITEM 780012) 
 Thoroughly reconstite the content of the vial with 1.2 ml of assay buffer. The 
preparation should be kept on ice during use and store at -20°C when not in use. Freezing 
and thawing of this solution should be limited to one time  
4-NITRATE STANDARD (ITEM NO. 780014) 
 Removing the vial stopper slowly to minimize disturbance of the lyophilized 
powder. Reconstitution of the contents of the vial with 1.0 ml of assay buffer. Vortex and 
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mix sufficiently to ensure all powder in the vial, including any on the stopper in solution. 
Storage is at 4°C when not in use. The reconstituted standard will be stable for about four 
months when stored at 4°C .  
5-NITRITE STANDARD (ITEM NO. 780016) 
 By removing the vial stopper slowly to minimize disturbance of the lyophilized 
powder. Reconstitution the content of the vial with 1.0 ml of assay buffer. Vortex and 
mix sufficiently to ensure all powder in the vial, including any on the topper. Is in 
solution. Store at 4°C when not in use. The reconstituted standard will be stable for about 
four months when stored at 4°C. 
6-GRIESS REAGENTS R1 AND R2 (ITEM NOS. 780018 AND 780020) 
 This is without adding any water or assay buffer to these reagents, as they are 
ready for use. These reagents should be stored at 4°C.  
SAMPLE PREPARATION  
 The kit has been validated in urine, culture media and plasma. NO sample 
purification from these sources is necessary other than some special instruction as 
described below. Storing of samples should be at -20°C or -80°C after collection. 
1. Urine Samples 
Urine can be used directly after dilution to the proper concentration in assay buffer. Urine 
contains relatively high levels of nitrate (200-2000 µM), so dilution of approximately 
1:10-1:50 may be necessary. 
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2. Culture Media 
Some types of tissue culture media contain very high nitrate levels (RPMI 1640). 
These types of media should not be used for cell culture if the goal of an experiment is to 
measure small changes in nitrate levels. Cellular nitrate/nitrite production can be 
quantitated by subtracting the level of nitrate/nitrite present in the media (in the absence 
of cells) from the total nitrate/nitrite level present during cell growth. The effect of media 
components on color development can be assessed by making a nitrite standard curve in 
the presence of a fixed volume of the culture media (40 µl works well ) and comparing it 
to a nitrite standard curve made in buffer alone. 
3. Plasma and serum samples 
  Ultrafiltration of plasma or serum samples through a 10 or 30 KDa molecular 
weight cut-off filter. The filters, supplied through Amicon or Millipore, are pre-rinsed 
with ultra pure water prior ultrafiltration. Ultrafiltration will reduce background 
absorbance due to the presence of hemoglobin and improve color formation using Griess 
reagents. Assay for nitate and / or nitrite using a maximum of 40 µl of the filtrate. The 
conversion of nitrate to nitrite requires three hours for completion.   
4. Tissue homogenates 
Homogenize the sample in PBS, pH 7.4 and centrifuge at 10000 x g for 20 
minutes. Ultracentrifuge the supernatant solution at 100000 x g for 30 minutes 
(centrifugation at 100000 x g is optional, but will increase filtration rates). Ultrafilter 
using a 10 or 30 kDa molecular weight cut-off filter using a commercially available 
centrifuge or microfuge ultrafiltration device. The filters supplied through Amicon or 
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Millipore, should be pre-rinsed with ultrapure water prior to ultrafiltration. Assay the 
sample for nitrate and/or nitrite using a maximum of 40 µl of the filtrate. The conversion 
of nitrate to nitrite requires three hours for completion.   
ASSAY PROTOCOL 
Plate set up 
There is no specific pattern for using the wells on the plate. However it is 
necessary to have some wells (at least two) designated as absorbance blanks (containing 
200 µl of assay buffer or water). The absorbance of these wells will be subtracted from 
the absorbance measured in all the other wells. Standard curves for nitrate and nitrite 
must also be included. Measuring only total NO products (nitrate + nitrite), only the 
nitrate standard curve is required. To measure only nitrite, the nitrite standard curve is 
needed. The wells for the standard curves have been designated (as A1-H2) in the 
instruction. However, these standard curves can be place in any wells. The remaining 
wells on the plate can then be used for the assay of samples, it is suggested to record the 
contents of each well on the template sheets provided .  
The kit provides sufficient cofactors and reagents to run two 96 well plates 
measuring total NO (NO2+NO3) in all the wells. In case of testing some samples for 
NO2 only (where reductase and cofactor are not required). There is sufficient Griess 
reagent R1 and R2 to run a third 96 well plate of nitrite determinations. All three plates 
are supplied with  kit.  
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MEASUREMENT OF NITRATE + NITRITE  
PREPARATION OF NITRATE STANDARD CURVE 
A nitrate standard curve must be preformed in order to quantitate sample nitrate + 
nitrite concentration. In a clean test tube place 0.9 of assay buffer and to this we add 0.1 
ml of reconstituted nitrate standard and vortex. The concentration of this stock standard is 
200 µM. We use this standard for the preparation of the nitrate standard curve as 
described below. The standard curve for nitrate is prepare by addition of reagents to the 
plate wells in the following way: 
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Nitrate standard concentration *the concentration is calculated for the final 200 
µl assay volume after addition of the Griess reagents. 
PREPARATION OF SAMPLES FOR TOTAL NITRATE+NITRITE MEASURMENT 
Samples containing nitrate (with or without nitrite) can be assayed by addition of 
up to 80 µl (40 µl with plasma or serum) of sample per well and be done in triplicare 
when using less than 80 µl of sample, the volume is adjusted to 80µl by addition of the 
appropriate amount of the assay buffer. When necessary, dilution of samples should be 
done using the assay buffer solution. In the event that the approximate concentration of 
nitrate or nitrite is completely unknown, it is recommended that several dilution of the 
sample is made. 
The absorbance of the samples should be between 0.05 and 1.2 absorbance units. 
Since the plate reader will give the most accurate values when the absorbance is in this 
range. In addition, high absorbance values imply high nitrate levels. Under these 
conditions, there may be incomplete conversion of nitrate to nitrite. The detection limit of 
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the assay is approximately 1µM nitrite. When using 80 µl of sample, this translates into 
2.5 µM nitrate in the original sample. 
• It is recommended that an adjustable pipette be used to deliver reagents to the 
wells. 
• Before pipetting each reagent , equilibrate the pipette tip in that reagent  
• Do not expose the pipette tip to the reagents already in the well. 
PERFORMING THE ASSAY 
1- Adding 200µl of water or assay buffer to the blank wells, do not add any other 
reagents to these wells.  
2- Adding up to 80 µl of sample dilution to the wells. The final volume must be 
adjusted to 80 µl using the assay buffer solution. NOTE plasma samples should 
be assayed with no more than 40 µl when undiluted samples are used (samples 
which have been diluted 1:2 or greater can use up to 80 µl in the assay). *Caution 
should be taken when pipetting plasma samples to ensure no bubbles enter to the 
well as this will lead to erroneous results. 
3- Adding 10 µl of the enzyme cofactor mixture to each of the wells.  
4- Adding 10 µl of the Nitrate reductase mixture to each of the wells.  
5- Cover the plate with the plate cover and incubate at room temperature for one 
hour and this incubation time should be increased to two hours when assaying 
tissue culture medium, and increased to three hours when assaying plasma or 
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tissue nitrate + nitrite concentration. It is not necessary to shake the plate during 
incubation.  
6- After the required incubation time, 50 µl of Griess reagent R1 is added to each of 
the wells.  
7- Add immediately 50 µl of Greiss reagent R2 to each of the wells.  
8- Allowing the color to develop for 10 minutes at room temperature, it is not 
necessary to cover the plate, this 10 minute incubation is optimal for color 
development however if the plate has been left to develop for longer time periods 
the data is still valid. Provided the Griess reagents have added to the standard 
curve at the same time as the unknowns ensures the presence of an accurate 
control.  
9- The absorbance reading is at 550 nm using a plate reader (Thermo scientific 
multiscan GO).  
Calculations 
Subtract the blanks. Average the absorbance value of the blank wells and subtract this 
from absorbance values of all the other wells. 
Plotting the standard curves: Make a plot of absorbance at 540-550 nm as a function of 
nitrite or nitrite concentration. The nitrate standard curve is used for determination of 
total nitrate + nitrite concentration, whereas the nitrite standard curve is used for 
determination of nitrite alone. In theory these two standard curves should be identical 
However, in practice a small discrepancy often occurs according to the kit guide.  
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Determination of sample nitrate or nitrite concentration  
 
 
Performance characteristics  
Precision: The inter assay coefficient of variation is 3.4%(n=5); The intra assay 
coefficient of variation is 2.7% (n=84). 
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Sensitivity: Using the maximum amount of sample for nitrate/nitrite assay (80 µl) , the 
detection limits is 2.5 µM . the detection limit for plasma is higher since only 40 µl of 
sample can be used . for the nitrite assay a maximum volume of 100 µl can be used . in 
this case the detection limit is approximately 2.0 µM. 
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APPENDIX C 
SUPEROXIDE DISMUTASE ASSAY PROTOCOL 
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About this assay  
Cayman’s superoxide dismutase assay kit utilizes a tetrazolium salt for detection 
of superoxide radicals generated by xanthine oxidase and hypoxanthine. One unit of SOD 
is defined as the amount of enzyme needed to exhibit 50% dismutation of superoxide 
radicals. The SOD assay measures all three types of SOD (Cu/Zn, Mn, and FeSOD). The 
assays provides a simple, reproducible and fast tool for assaying SOD activity in plasma, 
serum, erythrocyte lysates, tissue homogenates, and cell lysates. Mitochondrial MnSOD 
can be assayed separately following the procedure outlined under sample preparation. 
 
Scheme of superoxide dismutase assay 
PRE-ASSAY PREPARATION  
Reagent preparation  
1.Assay buffer (10x)-item No.706001: Dilute 3 ml of Assay Buffer concentration with 27 
ml of HPLC-grade water for assaying 96 wells. Prepare additional assay buffer as 
needed. This final Assay buffer (50 mM Tris-HCL, pH 8.0, containing 0.1 mM 
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diethylenetrianminepentaacetic acid (DTPA) and 0.1 mM hypoxanthine) will be used to 
dilute the radical detector. This diluted Assay Buffer is stable for at least 2 months when 
stored  at 4°C. 
2. SAMPLE BUFFER (10X)-item No.706003: Dilute 2 ml of sample buffer 
concentration with 18 ml of HPLC-grade water for assaying 96 wells. Prepare additional 
sample buffer as needed. This final sample buffer (50 mM Tris-HCL , pH 8.0) will be 
used to prepare the SOD standards and dilute the xanthine oxidase and SOD samples 
prior to assaying. This diluted sample buffer is stable for at least 6 months when stored at 
4°C. 
3. RADICAL DETECTOR (item No 706004): The vials contain 250 µl of tetrazolium 
salt solution. Prior to use, a 50 µl of the supplied solution is transferred to another vial 
and diluted with 119.95 ml of diluted assay buffer. Cover with tin foil. The diluted radical 
detector is stable for 2 hours. This is enough radical detector for 96 wells, the unused 
radical detector is stored at -20°C.  
4. SOD STANDARD – (item No.706005): The vials contain 100µl of bovine erythrocyte 
SOD (Cu/Zn). Store the thawed enzyme is stored on ice and preparing the standard curve 
will be discussed in the standard preparation section .the unused enzyme is stored at -
20°C. The enzyme is stable for at least two freeze/thaw cycles. 
5. XANTHINE OXIDASE – (item No. 706006): These vials contain 150 µl of Xanthine 
oxidase. Prior to use thaw one vial and transfer 50 µl of the supplied enzyme to another 
vial and diluting  with 1.95 ml of sample buffer (dilute). The thawed and diluted xanthine 
oxidase is stored on ice. The diluted enzyme is stable for one hour. This is enough 
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xanthine oxidase for 96 wells. The unused thawed should not be refreeze and should be 
thrown away. 
SAMPLE PREPARATION  
The procedures below listed for tissue homogenates and cell lysates will result in 
assaying total SOD activity (cytosolic and mitochondrial). To separate the two enzymes 
centrifuge the 1,500 x g supernatant at 10,000 x g for 15 minutes at 4°C. The 
resulting10,000 x g supernatant will contain cytosolic SOD and the pellet will contain 
mitochondrial SOD. Homogenize the mitochondrial pellet in cold buffer (20 mM Hepes , 
pH 7.2 containing 1 mM EGTA, 210 mM mannitol, and 70 mM sucrose). If not assaying 
on the same day, freeze the samples at -80°C. The samples will be stable for at least one 
month. The addition of 1-3 mM of potassium cyanide to the assay will inhibit both 
Cu/Zn-SOD and extracellular SOD resulting in the detection of only Mn-SOD activity. 
Samples can be assayed in the absence of Xanthine oxidase to generate a sample 
background. This sample background absorbance should be subtracted from the sample 
absorbance generated in the presence of Xanthine oxidase thus correcting for non SOD 
generated absorbance. 
Tissue homogenate 
1. Prior to dissection , either perfuse or rinse with phosphate buffered saline pH 7.4 to 
remove any red blood cells and clots. 
2. Homogenize the tissue in 5-10 ml of cold 20 mM HEPES buffer, pH7.2, containing 
1mM EGTA, 210 Mm mannitol, and 70 mM sucrose per gram tissue. 
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3. Centrifuge at 1,500 x g for five minutes at 4°C. 
4. Remove the supernatant for assay and store on ice. If not assaying on the same day 
freeze the sample at -80°C. The sample will be stable for at least one month. 
Cell lysate 
1. Collect cells by centrifugation at 1,000-2,000 x g for 10 minutes at 4°C. For adherent 
cells, do not harvest using proteolytic  enzymes , rather use a rubber policeman. 
2. Homogenize or sonicate the cell pellet in cold 20 mM HEPES buffer, pH7.2 containing 
1 mM EGTA, 210 mM mannitol, and 70 Mm sucrose. 
3. Centrifuge at 1,500 x g for five minutes at 4°C. 
4. Remove the supernatant for assay and store on ice. If not assaying on the same day, 
freeze the sample at -80°C. The sample will be stable for at least one month. 
Plasma and erythrocyte lysate 
1. Collect blood using an anticoagulant such as heparin, citrate or EDTA 
2. Centrifuge the blood at 700-1,000 x  g for 10 minutes at 4°C. Pipette off the top yellow 
plasma layer without disturbing the white buffy layer. Store plasma on ice until assaying 
or freeze at -80°C. The plasma sample will be stable for at least one month .plasma 
should be diluted 1:5 with sample buffer before assaying for SOD activity  
3. Remove the white buffy layer (leukocytes) and discard. 
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4. Lyse the erythrocytes ( red blood cells ) in four times its volume of ice-cold HPLC-
grade water.  
5. Centrifuge at 10,000 x g for 15 minutes at 4°C. 
6. Collect the supernatant (erythrocyte lysate) for assaying and store on ice. If not 
assaying the day, freeze at -80°C. The sample will be stable for at least one month. The 
erythrocyte lysate should be diluted 1:100 with sample buffer before assaying for SOD 
activity. 
Serum 
1. Collect blood without using an anticoagulant such as heparin, citrate or EDTA, allow 
blood to clot for 30 minutes at 25°C. 
2. Centrifuge the blood at 2,000 x g for 15 minutes at 4°C. Pipette off the top yellow 
serum layer without disturbing the white buffy layer. Store serum on ice. If not assaying 
the same day, freeze at -80°C. The sample will be stable for at least one month.  
3. Serum should be diluted 1:5 with sample buffer before assaying for SOD activity. 
ASSAY PROTOCOL  
Plate set up 
There is no specific pattern for using the wells on the plate. A typical layout of SOD 
standards and samples to be measured in duplicate is given below in the figure: 
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• It is recommended that an adjustable pipette be used to deliver reagents to the wells.  
• Before pipetting each reagent, equilibration is done to the pipette tip in that reagent 
(slowly filling the tip and gently expel the contents, repeating several times). 
• Do not expose the pipette tip to the reagents already in the well. 
General information  
• The final volume of the assay is 230 µl in all the wells.  
• The assay temperature is 25°C.  
• All reagents except samples and xanthine oxidase must be equilibrated to room 
temperature before beginning the assay.  
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• It is recommended that samples and SOD standards be assayed at least in duplicate. 
• The absorbance monitoring is at 440-460 nm using a plate reader. 
STANDARD PREPARATION  
Diluting 20 µl of the SOD standard (item No.706005) with 1.98 ml of sample buffer 
(dilute) to obtain the SOD stock solution. Take seven clean glass test tubes and mark 
them A-G and adding the amount of SOD stock and sample buffer to each tube as 
showing in the table. 
 
SUPEROXIDE DISMUTASE STANDARDS 
Performing the assay 
1. SOD standards wells – through adding 200 µl of the diluted radical 
detector and 10 µl of standard tubes A-G per well in the designated wells on 
the plate. 
2. Sample wells – through adding 200 µl of the diluted radical detector and 
10 µl detector and 10 µl of sample to the wells. 
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3. Initiating the reactions by adding 20 µl of diluted xanthine oxidase to all 
the wells using. It is important to precise the time of starting  adding the 
xanthine oxidase and as quickly as possible.  
4. Shaking the 96 well plate for few seconds to mix and covering with the 
plate cover. 
5. Incubation of the plate on a shaker for 20 minutes and reading the 
absorbance at 440-460 nm using a plate reader (Thermo Scientific Multiscan 
GO). 
Analysis 
Calculations 
1. Through calculation the average absorbance of each standard and sample 
and subtracting sample background absorbance from sample. 
2. Dividing standard A’s absorbance by itself and divide standard A’s 
absorbance by all the other standards and samples absorbance to yield the 
linearized rate (LR) which is stands for Std A = Abs Std A/Abs Std A;LR for 
Std B= Abs Std A/Abs Std B. 
3. We plotted the linearized SOD standard rat (LR) as a function of jinal 
SOD activity (U/ml) for a typical standard curve. 
4. The calculation of the SOD activity of the samples by using the equation 
obtained from the linear regression of the standard curve substituting the 
linearized rate (LR) for each sample. One unit is defined as the amount of 
enzyme needed to exhibit 50% dismutation of the superoxide radical. SOD 
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activity is standardized using the cytochrome c and xanthine oxidase coupled 
assay.  
 
 
Performance characteristics  
Precision: When a series of 60 SOD standard measurement were performed on 
the same day, the intra assay coefficient of variation was 3.2% and when a series 
of 60 SOD standard measurements were performed on five different days under 
the same experimental conditions, the inter assay coefficient of variation was 
3.7%. 
Assay range: Under the standardized conditions of the assay described , the 
dynamic range of the kit is 0.025-0.25 units /ml SOD. 
Representative superoxide dismutase standard curve: The standard curve 
presented here is an example of the data typically provided with this kit. 
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Superoxide dismutase standard curve 
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APPENDIX D 
ABBREVIATIONS 
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AgRP   agouti-related protein 
BMR  basal metabolic rate 
CYP450 cytochrome P450 
CVD  cardiovascular disease 
CCK  cholecystokinin 
CCF  cerebral spinal fluid 
COX-2 cyclooxygenase-2 
e NOS  endothelial nitric oxide synthase 
EDRFs endothelial-derived relaxing factors 
GCSF  granulocyte-colony stimulating factor 
GPCR  G protein coupled  receptors 
GLP-1  glucagon like peptide-1 
GPR120   G-protein coupled receptors 
i NOS  inducible nitric oxide synthase 
ICAM-1 intercellular cell-adhesion molecule-1 
 IL-6         interleukin 6 
INF-Y  interferon-y 
JAK  janus kinase enzyme 
LDL  low density lipoprotein 
LIF  leukemia inhibitory factor 
MEGJs myoendothelial gap junctions 
MCH  melanin concentrating hormone 
NO  nitric oxide 
NPY  neuropeptide Y 
NFk B  kappa B nuclear transcription factor 
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n NOS  neural nitric oxide synthase 
PPAR  peroxisome proliferator-activated receptor 
POMC  pro-opiomelanocortin 
PTPN 11 tyrosine-protein phosphatase non-receptor type 11 
PI3K  phosphatidylinositol 3-kinase 
PDE3B phosphodiesterase 3B, cGMP-inhibited 
POMC  proopiomelanocortin 
RANKL receptor activator of nuclear factor kappa-B ligand 
ROC3  receptor-operated channels 
RNS  reactive nitrogen species 
RXRβ  retinoid-activated nuclear receptor 
STAT  signal transducer and activator of transcription 
SOCS3 suppressor of cytokine signaling-3 
SOC3  store-operated channels 
TNF  tumor necrosis factor 
VCAM-1 vascular cell adhesion molecule-1 
 
 
